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ABSTRACT 
 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease affecting 
in excess of 26.6 million individuals globally. The neuropathological features of AD 
include extracellular deposition of amyloid beta (Aβ) plaques and intracellular 
neurofibrillary tangle formation. The cellular prion protein (PrPC) regulates the 
amyloidogenic cleavage pathway involved in Aβ shedding and interacts with the Aβ 
peptide. Given these interactions, the aim of this study was to investigate the 
influence of the 37kDa/67kDa laminin receptor (LRP/LR)- the cellular receptor for 
prion proteins- on Aβ shedding. Transfection of HEK293 cells with short hairpin 
RNAs (shRNAs) directed against LRP mRNA significantly decreased LRP levels in 
addition to Aβ shedding. Flow cytometric analysis revealed unchanged cell surface 
levels of the amyloid precursor protein (APP), β-secretase and γ-secretase after 
transfection of cells with shRNAs, suggesting a role of LRP/LR in Aβ shedding via a 
mechanism independent of gene-expression modulation of these key proteins. LRP-
shRNA treatment significantly reduced sAPPβ expression, implicating LRP/LR in 
APP processing specifically via augmenting the activity of β-secretase. Co-
localisation of LRP/LR with APP, β- and γ-secretase, respectively, alludes to a 
possible interaction between said proteins. Therefore, LRP-shRNAs are suggested as 
alternative therapeutic tools for AD treatment.  
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CHAPTER 1 
 
1. Introduction 
 
1.1. Alzheimer’s disease: An introduction 
Alzheimer’s disease (AD), also referred to as Alzheimer’s dementia, Morbus 
Alzheimer’s or simply Alzheimer’s, is a progressive neurodegenerative disorder that 
is by far the most common form of dementia globally1. Initially, patients with the 
disease present with symptoms including disruptions in short-term memory, attention, 
language, personality and spatial orientation, in association with confusion and erratic 
mood changes2. These memory and other cognitive functions progressively become 
impaired over a time period of 8 to 10 years, resulting in characteristic 
neurodegenerative changes and the complete dependency and ultimate death of the 
patient3. Neurodegeneration typically begins within the entorhinal cortex, spreading in 
a well-defined manner to other regions of the brain, in particular the parietal and 
temporal regions of the neocortex, as well as the hippocampus3; 4; 5.  
 
Mounting AD research has been driven not only due to unclear disease etiology, but 
also due to the rise in life expectancies and subsequent number of individuals at risk 
for the disease6. In spite of tireless research endeavors, no known cures or treatments 
are available to halt the degeneration of neuronal cells in AD. However, the U.S. Food 
and Drug Administration (FDA) has approved 5 palliative therapies that have been 
shown to slow the symptoms of AD for an average of a year in approximately 50% of 
all individuals on therapy7. It is estimated, that over 90 drugs are currently in clinical 
trials, aimed at slowing the advancement of the disease7. The further development of 
therapies and their potential ability in slowing the progression of neurodegenerative 
changes linked to AD is crucial for the effective management of the burden of the 
disease.  
 
1.2. Epidemiology of AD 
In  2010, the global number of dementia patients was reported to be 35.6 million, a 
figure expected to double every 20 years, to 65.7 million in 2030, and 115.4 million in 
! 2!
2050 (Alzheimer’s disease interactional: World Alzheimer Report 2009). It is 
suggested that this increase can mainly be attributed to a rise in the number of 
dementia cases within low and middle-income countries. The worldwide incidence 
rate of AD is estimated to be approximately 0.5% per year among individuals aged 
65-70 to 6-8% in individuals over 85 years of age8.  Within South Africa, more than 
250 000 individuals are currently afflicted by the disease (Statistics South Africa), 
while 5.4 million Americans of all ages are estimated to have Alzheimer’s disease in 
2012 (2012 Alzheimer’s disease facts and figures). In the United States a new case of 
AD develops every 69 seconds - a time expected to accelerate to 33 seconds by 20508.  
Moreover, in the United States in 2006, AD was reported to be the 7th most prevalent 
cause of death across all age groups, and the 5th leading cause of death amongst those 
65 years of age and older9.  
 
Given the increasing lifespan of the population, the burden of AD will only grow 
more significant. In 2011, the first baby boomers will reach their 65th birthdays. By 
2029, all baby boomers will be at least 65 years of age. This group aged 65 years and 
older will have a significant impact on the healthcare system7. According to the World 
Alzheimer Report 2010, the total estimated worldwide cost of dementia was US$604 
billion in 2010, accounting for approximately 1% of the world’s gross domestic 
product. Low-income countries were accountable for 1% of total global costs, in spite 
of a 14% prevalence rate, as opposed to middle and high-income countries that 
accounted for 10% (but 40% prevalence) and 89% (but 46% of the prevalence) of 
costs, respectively. Moreover, 58% of costs within low-income countries were 
attributed to informal care, compared to 65% and 40% in middle and high-income 
countries, respectively. Conversely, high-income countries accounted for 
approximately 50% of costs due to professional care equivalent of nursing homes, as 
opposed to 10% for lower income countries.  
 
1.3. Genetics of AD 
With the exception of age, family history is the greatest risk factor for AD, with twin 
and family studies estimating that 80% of all AD cases have a genetic link10. This 
disease is genetically dichotomous, with two main forms having been identified: (i) 
early-onset familial AD (EO-FAD) afflicting a small minority of (<5%) of all AD 
! 3!
patients, typically before the age of 60, and characterised by Mendelian inheritance, 
and (ii) late-onset AD (LOAD) which accounts for the vast majority of all AD cases 
and is influenced by both genetic variants and lifestyle choices11; 12.  
 
1.3.1. Early-onset familial AD 
Rare mutations in three genes have been strongly linked to EO-FAD: Amyloid 
Precursor Protein (APP) on chromosome 21q21 and the presenilin encoding genes 
(PSEN1 and PSEN2) located on chromosomes 14q24 and 1q31, respectively (Table 
1.1). To date, 24 mutations have been identified in APP, 185 in PSEN1 and 14 in 
PSEN2 (Alzheimer Disease and Frontotemporal Dementia Mutation Database; 
http://www.molgen.ua.ac.be/ADMutations). With the exception of one of the >200 
EO-FAD linked mutations (PSEN2-N141I), all others are inherited in an autosomal-
dominant manner and lead to a common phenotype: an increased Aβ42:Aβ40 ratio11; 13. 
The relative increase in Aβ42 ultimately results in aggregation of the protein and early-
onset of the disease, usually within the fourth or fifth decade of life14. APP mutations, 
which are typically of the missense type, accounts for less than 1% of all AD patients 
and influence APP proteolytic processing and/or aggregation due to their positioning 
either on or near the Aβ-coding exon6. By far, the most prevalent AD-related 
mutations are of the PSEN genes15. The vast majority of these mutations are single-
nucleotide substitutions; however small insertions and deletions have also been 
identified16. γ-secretase-mediated cleavage of APP is affected by PSEN mutations, 
resulting in an increased Aβ42:Aβ40 ratio, alluding to a loss- rather than a gain-of-
function16.  
 
Table 1.1| Early-onset familial AD genes and their resultant molecular phenotype 
Gene$ Protein$ Chromosome$ Mutations$ Molecular$
phenotype$
APP# Amyloid(
precursor(
protein(
21q21( 24((duplication)( ↑(Aβ42:Aβ40(
↑ Aβ production 
↑ Aβ 
aggregation(
PSEN1# Presenilin(1( 14q24( 185( ↑(Aβ42:Aβ40(
PSEN2# Presenilin(2( 1q31( 14( ↑(Aβ42:Aβ40(
*(Adapted from 16). 
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1.3.2. Late-onset AD 
As opposed to EO-FAD which is characterised as being autosomal dominant, 
displaying classical Mendelian inheritance, LOAD inheritance is genetically complex 
in which genetic factors together with environmental and lifestyle factors contribute 
to the lifetime risk for AD12. A single gene variant, the ε4 allele of the apolipoprotein 
E gene (APOE) located on chromosome 19q13, is the only LOAD-risk factor 
consistently reported to attribute to AD17 (Table 1.2). The three major alleles of 
APOE differ in terms of amino acid combinations at residues 112 and 158 (ε2: 
Cys112/Cys158; ε3: Cys112:Arg158; ε4: Arg112/Arg158). The APOE ε4 allele affects both 
risk as well as age of disease onset in a dose dependant manner, with risk profile 
increasing fourfold when inherited as a single copy and by more than 10-fold for a 
double-dose. The ε3 allele is considered neutral, neither enhancing nor reducing AD-
risk profile, while the ε2 allele is protective in nature6; 18. APOE has a biological 
function in lipid metabolism and transport but is believed to function in Aβ clearance 
from AD brains16. In addition Genome Wide Association Studies (GWAS) have 
identified statistically significant AD variants in the following genes:  CD33, CLU, 
CR1, PICALM, BIN1, ABCA7, CD2AP, EPHA1, MS4A6A/MS4A4E and ATXN116 
(Table 1.2). Functionally, these genes contribute to AD pathogenesis through (i) 
production, clearance and degradation of Aβ, (ii) lipid metabolism, (iii) innate 
immunity or, (iv) cell signaling16.  
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Table 1.2: Late-onset AD genes and their proposed molecular mechanism 
Gene$ Protein$ Chromosome$ Risk$
change$
(%)$
Molecular$
phenotype$
APOE# Apolipoprotein(E( 19q13( 400@1500( Aβ(clearance;(
lipid(
metabolism(
CD33# CD33( 13q13.3( 10( Innate(
immunity;(Aβ(
degradation(
CLU# Clusterin( 8p21.1( 10( Aβ(clearance;(
innate(
immunity(
CR1# Complement(
component((3b/4b)(
receptor(1(
1q32( 15( Aβ(clearance;(
innate(
immunity(
PICALM# Phosphatidylinsoitol(
binding(clathrin(
assembly(molecule(
11q14( 15( Aβ(
production(
and(
clearance;(
cell(signaling(
BIN1# Bridging(integrator(
1(
2q14( 15( Aβ(
production(
and(
clearance;(
cell(signaling(
ABCA7# ATP@binding(
cassette(subfamily(
A(member((7(
19p13.3( 20( Lipid(
metabolism;(
cell(signaling(
CD2AP# CD2@associated(
protein(
6p12.3( 10( Cell(signaling(
EPHA1# EPH(receptor(A1(( 7q34( 10( Cell(signaling;(
innate(
immunity(
MS4A6A/MS4A4E# Membrane@
spanning(4@
domains,(subfamily(
A,(members(6A(and(
4E(
11q12.1( 10( Cell(signaling(
ATXN1# Ataxin(1( 6p22.3( NA( Aβ(
production(
*NA: Not applicable. (Adapted from 16). 
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1.4. Neuropathological alterations in AD 
The neuropathological hallmarks of AD include both ‘positive’ and ‘negative’ lesions. 
Typical ‘positive’ features consist of (i) amyloid plaques composed of extracellular 
deposits of the amyloid beta peptide (Aβ), (ii) neurofibrillary tangles (NFTs) 
comprised of a hyperphosphorylated form of the microtubule associated protein, tau, 
(iii) neuropil threads consisting of axonal and dendritic regions associated with 
aggregated tau, and (iv) dystrophic neuritis19; 20; 21; 22; 23. These features are generally 
accompanied by astrogliosis24; 25 and microglial cell activation25; 26, in addition to 
cerebral amyloid angiopathy (the deposition of Aβ in the meningeal arteries and 
cortical capillaries, particularly in posterior regions of the brain)19. Neuronal, 
neurophil and synaptic losses are classical ‘negative’ AD-associated lesions 
accompanying the aforementioned ‘positive’ features of AD27; 28; 29; 30; 31; 32.  
 
1.4.1. Neuritic plaques 
At the microscopic level, one of the defining features of AD is neuritic plaque 
formation33. Plaques, which form predominately within the limbic and associated 
cortices, are composed of extracellular deposits of Aβ surrounded by dystrophic 
neurites, reactive astrocytes and microglia33 (Fig. 1.1). The Aβ peptide, which is 
constitutively produced and readily detectable in the cerebrospinal fluid (CSF), has a 
range of isoforms between 38 and 43 amino acids34. The two predominate isoforms, 
Aβ42- the more fibrillary form with an increased propensity for aggregartion- and 
Aβ40 occur at relative proportions of 1:9 respectively35.  These proportions are altered 
in AD patients, such that the levels of Aβ42 are higher than that of Aβ40 35.  
 
 
! 7!
 
Fig. 1.1| Brain section showing AD related amyloid plaques and neurofibrillary tangles in the cerebral cortex.  Plaques are composed of extracellular 
deposits of Aβ surrounded by dystrophic neurites, reactive astrocytes and microglia, whereas NFTs are composed of intracellular aggregates of the 
hyperphosphorylated microtubule-associated protein, tau (Adapted from 36).  
Plaque 
Neurofibillary,
tangle 
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1.4.2. Amyloid cascade hypothesis 
To date the amyloid cascade hypothesis remains the most favorable framework to 
explain AD pathogenesis (Fig. 1.2). Although widely contested, this hypothesis is the 
most well studied and defined model for the cause of AD37. As originally described in 
the 1990’s, the amyloid cascade hypothesis proposes that AD is a result of plaque 
formation due to either an increased production or decreased clearance of Aβ38; 39. 
Aggregated Aβ and subsequent plaque formation, triggers a cascade of neurological 
changes, the end result being neuronal death and associated dementia.  
 
Several alterations, in terms of the pathogenic state of Aβ have arisen over time (Fig. 
1.3). The original hypothesis that states that plaques are the pathogenic agents 
responsible for AD (Fig. 1.3a) has lost credibility based on the following findings: (i) 
severity of dementia is poorly correlated to plaque load31,  (ii) many AD patients who 
present with severe cognitive decline and memory impairment do not display plaque 
formation upon post-mortem analysis, and (iii) in vivo neuroimaging techniques have 
revealed the presence of plaques in healthy individuals40; 41. The preceding evidence 
suggests that amyloid plaques are not the pathological species that trigger AD, but 
rather may be benign or protective in nature42.  
 
Subsequently, studies showing that mutations associated with familial AD increase 
Aβ42 production, led to the hypothesis that increased Aβ42 levels are the causative 
agent of AD43 (Fig. 1.3b). Yet another alternative of the amyloid cascade hypothesis 
states that it is not the level of Aβ42 that is important for AD pathogenesis, but rather 
the ratio of Aβ42:Aβ40 37 (Fig. 1.3c).  This alternative hypothesis is largely based on 
the inverse correlation between age of onset of AD and Aβ42:Aβ40 ratio44. However, 
several lines of investigative efforts now support the view that increased levels of 
soluble Aβ42 oligomers, ranging in size from 2 to 12 subunits, lead to 
neurodegeneration and synaptic damage45; 46; 47; 48; 49 (Fig. 1.3d). In vitro, Aβ 
oligomers have been shown to inhibit long-term potentiation (LTP), damage neuronal 
spines and thwart activity-regulated cytoskeletal associated protein distribution46; 50; 51; 
52. Similar Aβ oligomeric species have been identified in APP transgenic mouse 
models, as well as in the brains53; 54; 55 and CSF of AD patients56; however, the 
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correlation between oligomer accumulation and severity of cognitive impairment 
remains evasive53; 54; 55.  
 
 
Fig. 1.2| Amyloid cascade hypothesis. According to the amyloid cascade hypothesis AD 
pathogenesis is the result of an increased production or decreased clearance of Aβ, ultimately 
leading to Aβ accumulation, aggregation and plaques formation. Aβ oligomers are believed to 
inhibit long-term potentiation and impair synaptic functioning, while aggregated and 
deposited Aβ has been linked to an inflammatory response and oxidative stress. These 
processes are believed to be responsible for neuronal and synaptic dysfunction, as well as 
neurotransmitter deficits, leading to the cognitive symptoms associated with AD. Although 
regarded as a down-steam event, tangle formation is thought to contribute to neuronal loss 
and cognitive decline (Adapted from 33).  
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Fig. 1.3| Alternatives to the originally proposed amyloid cascade hypothesis. The primary 
claim of the amyloid hypothesis is that Aβ is largely responsible for AD pathogenesis. (a) It 
was originally proposed that increased levels of Aβ result in plaque formation, the latter being 
the agent responsible agent for causing AD. (b) Subsequent studies led to the hypothesis that 
increased levels of Aβ42 are the pathogenic species responsible for the disease. (c) Later it 
was proposed that the Aβ42:Aβ40 ratio, rather than the levels of Ab42, is important in disease 
pathogenesis. (d) However, recently it has been suggested that soluble Aβ oligomers are the 
toxic species responsible for AD development (Adapted from 37). 
 
 
1.4.3. Neurofibrillary tangles 
In addition to neuritic plaque formation, numerous neurons that are typically affected 
in AD brains contain large, non-membranous bundles of insoluble filaments within 
the perinuclear cytoplasm33. These neurofibrillary tangles (NFTs) were shown to be 
composed of a hyperphosphorylated form of the microtubule-associated protein, tau57; 
58 assembled into paired helical filaments (PHFs); that is, fibrils of approximately 
10nm in diameter that form pairs with a helical conformation at a regular periodicity 
of 65nm59; 60; 61. However, recent in vitro evidence has alluded to the presence of 
twisted ribbon-like assemblies of tau fibrils, thus disputing the PHF concept62. 
Nonetheless, tau, which functions in microtubule assembly and stability, is tightly 
regulated with respect to its degree of phosphorylation by various kinases (e.g. GSK-
3ß and CDK5) and phosphatases (e.g. PP-1 and PP-2A)63 (Fig. 1.4). Disassembly of 
microtubules and the associated disruption in axonal transport, both of which result in 
synaptic dysfunction and neuronal death, are the consequence of hyperphosphorylated 
tau sequestration of normal tau and other microtubule-associated proteins63. The 
topographical progression of NFTs (and neurophil threads) occurs in a predictable 
manner, with tangle formation initially affecting the transentorhinal region, and then 
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spreading to the amygdala and hippocampus, and eventually to the neocortical areas 
of the brain64; 65; 66; 67.  
 
Whether NFT formation is a precursor of neuronal loss or merely a protective marker 
of other AD-related processes is still in question. However, multiple groups have 
established a strong correlation between the amount and distribution of NFTs with the 
severity of dementia32; 68; 69; 70; 71. In addition, the topographical distribution of NFTs 
is in accord with the hierarchical neuropsychological profile associated with AD, 
occurring prior to plaque deposition19. Nonetheless, these tangles are not only 
associated with AD pathology, but also a number of other neurodegenerative diseases 
and disorders, such as subacute sclerosing panencephalitis72. Although Aβ neuritic 
plaques have been described in the brains of healthy individuals not afflicted with 
AD, as well as patients suffering from dementia with Lewy bodies, it is not the 
primary lesion defining any disease other than AD72. Moreover, mutations within the 
tau gene results in the development of frontotemporal dementia (as opposed to AD)73, 
while mutations resulting in an increased shedding of Aβ42 are clearly linked to the 
development of familial AD72. As such, it is largely believed that Aβ is the primary 
causative agent in AD. 
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Fig. 1.4| Tau hyperphosphorylation and tangle formation in AD. The balance between 
normally phosphorylated and abnormally hyperphosphorylated tau is regulated by multiple 
kinases and phosphatases. Hyperphosphorylated tau sequesters normal tau and other 
microtubule-associated proteins, resulting in microtubule disassembly and disrupted axonal 
transport. Additionally, abnormally phosphorylated tau may aggregate into insoluble paired 
helical filaments and larger tangles. It is both tau polymerization and microtubule disassembly 
that is responsible for neuronal and synaptic dysfunction, ultimately leading to neuronal death 
and dementia (Adapted from 33).  
 
 
1.5. Origin of amyloid β-protein: Cell biology of APP 
The realisation that Aβ was the main component of AD-associated plaques74; 75 led to 
the subsequent need to elucidate the origins of this protein. It was found that Aβ was 
the derivative of the sequential proteolytic processing of the type I transmembrane 
protein, amyloid precursor protein (APP)72 (Fig. 1.5). APP is heterogenic in nature, 
the result of (i) alternate mRNA splicing, giving rise to three isoforms (695, 751 and 
Normal'tau'protein 
Hyperphosphorylated'tau 
Sequestration'of'tau,'MAP1'
&'MAP2 
Tau'polymerisation Microtubule'disassembly 
Disrupted'axonal'transport Tangle'formation 
Neuronal'&'synaptic'
dysfunction 
DEMENTIA 
Neuronal'death 
Phosphatases Kinases 
! 13!
770 amino acid residues in length) and (ii) post-translational modifications including 
N- and O-linked glycosylation, phosphorylation and sulphation76; 77; 78; 79. APP751 and 
APP770 isoforms are ubiquitously expressed, predominantly within non-neuronal cells, 
while the APP695 isoform has largely been isolated from neuronal tissue80. The 37-43 
amino acid Aβ peptide is located in part between the ecto- and transmembrane 
domain of APP81. Specifically, the Aβ sequence extends 28 residues into the 
extracellular domain and between 11 and 15 residues into the transmembrane domain, 
depending on the length of Aβ to be released81. Although APP maturation and 
trafficking occurs throughout the secretory pathway, it is proteolytically processed by 
three different secretases (α-, β- and γ-secretase) at various subcellular sites, with the 
sequential cleavage of β- and γ-secretase resulting in Aβ production.  
 
Fig. 1.5| Schematic representation of APP. APP is a type I transmembrane protein 695 
amino acids in length. The Aβ sequence is shown in relation to APP, together with the α-, β-, 
and γ-secretase cleavage sites. β-secretase cleaves at residues 1 of the Aβ sequence, while γ-
secretase cleaves at amino acid 16 of this same sequence. γ-secretase cleaves at residues 38, 
40 or 42 depending on whether Aβ38, Aβ40 or Aβ42 is produced, respectively.  
(Adapted from 36). 
 
1.5.1. Proteolytic processing of APP 
APP is a transmembrane protein that is translocated to the endoplasmic reticulum 
(ER) co-translationally by its signal peptide, where it then undergoes post-
translational modifications within the secretory pathway72. APP is cleaved 
differentially by α-, β- and γ-secretase giving rise to two APP cleavage pathways: (i) 
an Aβ synthesizing amyloidogenic pathway and (ii) a non-pathogenic, non-
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amyloidogenic pathway (Fig. 1.6). Although both of these pathways occur 
constitutively throughout the lifetime of an individual, the amyloidogenic processing 
of APP is favored in neuronal cells mostly due to high β-secretase expression levels82. 
The non-amyloidogenic processing of APP occurs predominantly in all other cell 
types83; 84; 85; 86. There is also some evidence supporting the competition between these 
two pathways, whereby enhanced γ-secretase activity decreases the shedding of Aβ 
and subsequent plaque formation87; 88.  
 
The non-amyloidogenic APP processing pathway involves the cleavage of APP at 
Lys16 within the Aβ region (or between amino acid residues 105 and 125 depending 
on the APP isoform) by α-secretase, and hence precludes Aβ formation89; 90 (Fig. 
1.5/Fig. 1.6). This processing results in the release of the large, soluble ectodomain of 
APP, namely sAPPα, into the extracellular space72; 82. The resultant 83 residue long 
C-terminal portion of APP, designated C83, is retained within the membrane72; 82. The 
vast majority of sAPPα is formed by α-secretase cleavage of APP inserted within the 
plasma membrane91; 92. However, sAPPα can also be formed during the intracellular 
secretory processing of APP93. α-secretase activity is mediated by one or more 
enzymes belonging to the family of disintegrin and metalloproteinase domain proteins 
(ADAMs), where it has been hypothesised that ADAMs 9, 10, 17 and 19 are most 
likely responsible for α-secretase activity94; 95; 96. The C83 fragment undergoes 
subsequent cleavage by γ-secretase at amino acid residues 711 or 713 72. γ-secretase 
cleavage of C83 results in the generation of a 3kDa peptide called p3, as well as the 
amino-terminal APP intracellular domain (AICD)84; 89 (Fig. 1.6).  
 
Some APP does not undergo cleavage by α-secretase, but is rather cleaved 16 
residues N-terminal to the α-secretase cleavage site (or at the N-terminal of the Aβ 
region) by an enzyme referred to as β-secretase97 (Fig. 1.5/Fig. 1.6). This pathway 
that involves the formation of Aβ is referred to as the amyloidogenic pathway. 
Cleavage by β-secretase generates a slightly smaller ectodomain fragment, sAPPß, and 
the C-terminal fragment 99 residues in length (C99) that is retained within the cellular 
membrane97; 98. Although β-secretase cleavage predominantly occurs on the cell 
membrane, it also occurs to a smaller extent in the secretory trafficking of APP93. 
C99, which begins at residue 1 of the Aβ region, is subsequently cleaved by γ-
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secretase at residues 38, 40 or 42 to release Aβ38, Aβ40 or Aβ42, respectively90; 99 (Fig. 
1.5/Fig. 1.6). In addition to Aβ shedding, γ-secretase cleavage results in the remaining 
C-terminal fragment of APP referred to as AICD, being released into the 
cytoplasm100; 101; 102.  
 
Although γ-secretase cleavage of APP results in the release of Aβ and an AICD 
fragment 57 or 59 residues in length (C57 and C59, respectively), an additional 
cleavage site (ε-cleavage site) is located 7 to 9 amino acids towards the C-terminal 
end101. γ-secretase cleavage at the aforementioned site results in the formation of an 
AICD fragments 50 amino acids in length (C50)101. This 50 residue long fragment is 
the predominant AICD form, however, AICD fragments as short as 31 residues have 
been reported101.  
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Fig. 1.6| APP processing and cleavage in AD pathogenesis. The non-amyloidogenic 
pathway (right) involves the sequencial cleavage by α- and γ-secretase, resulting in the 
formation of sAPPα and various C-terminal fragments (C83, p3 and AICD). The 
amyloidogenic pathway (left) involves the sequential cleavage by β- and γ-secretase 
generating sAPPβ and the following C-terminal fragments: C89 or C99, Aβ, and AICD. Aβ 
fragment oligomerisation and fibrillation results in AD pathogenesis (top panel). α: α-
secretase; β: β-secretase; γ: γ-secretase. (Adapted from 101) 
 
1.5.2. The amyloidogenic proteases: β- and γ-secretase 
β-secretase 
β-secretase is a membrane-bound enzyme displaying a high level of homology to the 
pepsin family of aspartyl proteases103 and mediates the initial and rate-limiting step of 
the amyloidogenic pathway104. The predominant β-secretase within the central 
nervous system was identified as the β-site APP cleaving enzyme 1 (BACE1)105. 
BACE1 is the sole β-secretase involved in Aβ generation, as its knockout ablates Aβ 
shedding106; 107. BACE2, a homologue of BACE1, has also been identified104 but 
found to exert an anti-amyloidogenic effect in non-neuronal cells108; 109; 110; 111. 
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Although ubiquitously expressed, BACE1 levels are most prominent within brain and 
pancreatic tissues82. The concomitant high expression of APP within the brain 
provides an explanation for Aβ aggregation predominantly within neuronal tissue 
despite ubiquitous expression of both APP and BACE182.  
 
The therapeutic targeting of BACE1 is substantiated as its blockage in activity is 
associated with a decrease in the shedding of Aβ and accumulation in the β-carboxy 
terminal fragment112. The later being an additional possible contributor of neurotoxic 
effects82. Although progress has been made towards the production of a successful 
BACE1 inhibitor112, possible side-effects as a result of the inhibition of physiological 
BACE1 function have deterred the advancement of many clinical trials. Indeed, one 
of the physiological functions of BACE1 involves Schwann cell-mediated 
myelination via the Neuregulin-1 (NRG1) signaling pathway113, with BACE1 
knockout mice displaying a significant hypomyelination phenotype114; 115.   
 
γ-secretase 
γ-secretase is an intramembranous multi-complex protein, consisting of four subunits: 
(i) presenilin (PS) 1 or 2 which contain two catalytic aspartyl residues within 
transmembrane domains 6 and 7 116, (ii) PS enhancer 2 (PEN2)117, (iii) nicastrin 
(NCT)118 and (iv) anterior pharynx defective (APH)-1a or APH-1b117. While little is 
known about the physiological function of PEN2, NCT and APH-1, all four 
components are necessary for efficient γ-secretase activity119. It has been 
hypothesized that NCT plays a role as a size selecting substrate receptor120; 121, yet 
recent evidence has challenged this view122; 123. PEN-2 has been proposed to mediate 
PS endoproteolysis and stabilization within the γ-secretase complex124; 125, while 
APH-1 is thought to possibly act as a scaffold for NCT binding126.  
 
 
1.5.3. Functions of APP and its derivatives 
It is difficult to ascertain a definite physiological function for APP, without 
considering its proteolytic cleavage derivatives101. Nonetheless, an overexpression of 
human APP has been linked to increased size of neurons within the cortex127. It is still 
unknown as to whether this increase in neuronal size is attributed to the full-length 
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APP or one of its cleavage derivatives127. Moreover, APP knockout mice display 
numerous altered phenotypes including a reduction in brain and body size, 
impairment in learning, increased propensity for seizures, as well as abnormal 
development of the corpus callosum128; 129. The extracellular domain of APP interacts 
with a variety of extracellular matrix molecules including heparin130; 131, laminin132 
and collagen type I133, implicating APP in cell adhesion. Moreover, APP has been 
identified as a novel class of synaptic adhesion molecules129. Evidence from 
numerous sources now implicates APP in neural- and synapto-trophic functions. The 
ablation or reduction in APP results in impaired neuronal viability in vitro and 
decreased synaptic activity in vivo134; 135; 136.  
 
Although the physiological function of sAPPα is still largely undetermined, it is 
believed that sAPPα is beneficial to neurons101 (Fig. 1.6). sAPPα is thought to play a 
neuroprotective function against oxygen-glucose deprivation and excitotoxicity by 
stabilizing the resting membrane potential137; 138. sAPPα has also been implicated in 
the promotion of neurite outgrowth, cell adhesion and synapse formation139; 140. In 
contrast, sAPPβ is not associated with any of the neuroprotective effects as with 
sAPPα138. sAPPβ has been shown to be crucial in synaptic pruning during the 
development of neurons within the central and peripheral nervous system141 (Fig. 
1.6). sAPPβ has also been hypothesised to inhibit neuronal stem cell differentiation, 
while promoting the differentiation of glial cells142.  
 
The AICD has been shown to contain the consensus sequence, YENPTY. This 
sequence is believed to be vital in the functioning of AICD, as well as its binding to 
adaptor molecules, for example Fe65143.  With regards to its signaling pathway, AICD 
has been found to bind to Fe65, followed by the sequestration of histone deacetylase 
TIP60, and its subsequent translocation into the nucleus144; 145; 146 (Fig. 1.6). Here it 
acts as a transcriptional factor for p53147, GSK3β148; 149, neprilysin150, EGFR151, in 
addition to others101; 129. To date, the biological functions of the p3, C83, and C99 
fragments have not been determined101.  
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1.6. Prion proteins: An introduction 
Prions (PrP or proteinaceous infectious particles) are the causative agent of 
transmissible spongiform encephalopathies (TSEs)152. This group of mammalian 
associated neurodegenerative diseases encompasses scrapie in sheep, bovine 
spongiform encephalopathy (BSE) in cattle, chronic wasting disease in cervids, and 
kuru, familial fatal insomnia, Creutzfeldt-Jakob disease (CJD), and Gerstmann-
Sträussler-Scheinker syndrome in humans153; 154; 155; 156; 157; 158; 159. These TSEs are rare 
and have a prevalence rate (in humans) of approximately one per one million 
individuals160. TSEs may arise either spontaneously, through heritable mutations in 
the PRNP gene, or be transmitted via an infectious route160. Subsequent to an 
extended incubation period, those afflicted with the disease present with symptoms 
including cognitive and motor dysfunction, as well as cerebral ataxia160. Further, TSE 
diseased brains are characterized by astrogliosis, spongiform degeneration, and 
aggregates of misfolded protein154; 156; 157.  
 
It is generally accepted that the cellular isoform of PrP, PrPc, is post-translationally 
misfolded into the infectious scrapie form of PrP, namely PrPSc 161.  According to the 
protein-only hypothesis, the oligomeric β-sheet rich PrPSc is propagated via binding to 
endogenous PrPc- the interaction sufficient to cause the template-driven refolding into 
the infectious PrPSc isoform71-77. There is growing evidence in support of this 
hypothesis which explains that the transmission of TSEs do not require nucleic acids, 
but rather PrPSc alone is able to act as the infectious agent160.  
 
PrPc is expressed in particularly high amounts on the neuronal cell surface, but is also 
expressed on the cell surface of a number of other cell types161. This glycosyl-
phosphatidylinositol anchored protein consists of a flexible N-terminus and a globular 
C-terminus, mostly α-helical in nature162. The physiological role of PrPc has yet to be 
fully elucidated but hypotheses include cell adhesion, ion channel activity, neurite 
outgrowth, neuronal excitability, cytotoxicity and cytoprotection152. Nonetheless, PrP-
deficient mice have been shown to display only very mild phenotypic abnormalities; 
for example, changes in myelination163 and olfactory function164. Proposed PrPc 
binding partners are numerous, with it being suggested that some of these binding 
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partners are not only important to PrPc function but also to the PrPc→PrPSc 
conformation conversion process165; 166; 167.  
 
1.7. Linking prion proteins and Alzheimer’s disease 
A number of studies have provided both genetic and neuropathological similarities 
between AD and the PrP-linked TSEs. AD-associated pathology has been reported 
within individuals with CJD168, while PrPc has been shown to co-localise with Aβ in 
plaques169. It was further determined that patients with CJD, presenting with AD-
associated pathology, often develop these Aβ-PrPc co-localised plaques170. Both AD 
and CJD risk is enhanced by the APOE4 allele and decreased by the APOE2 allele. 
Moreover, APOE binds to numerous amyloidogenic proteins, including Aβ and PrP, 
with histological studies revealing APOE’s association with Aβ and kuru-like plaques 
of AD and CJD brains, respectively. A possible role of PrPc promotion of Aβ 
formation has also been suggested171. Studies have revealed PRNP as a potential AD 
susceptibility gene172, with the Met/Val 129 polymorphism being linked to the early 
onset of AD170; 173; 174, as well as long term memory175 and early cognitive decline176. 
Total PrP levels within the CSF have been linked to increased disease severity in AD, 
in addition to other neurodegenerative disorders177; 178. In spite of these genetic and 
pathological links between AD and PrP, a definitive role of PrP in APP processing 
was identified only recently179.  
 
1.7.1. Regulatory role of prions in APP processing 
In 2007, Parkin et al.179 reported that PrPc mediates a decrease in the amyloidogenic 
cleavage of APP, and hence a reduction in Aβ shedding. The initial results, produced 
in human neuroblastoma cell lines induced to overexpress PrPc, revealed decreased 
levels of both sAPPβ and Aβ179. Further, the siRNA-induced silencing or genetic 
knockout of PrPc within murine neuroblastoma (N2a) cells resulted in increased Aβ 
levels179. Changes in the levels of sAPPβ in response to PrPc led to the conclusion that 
PrPc is able to influence APP processing and hence Aβ shedding by decreasing 
cleavage of APP by BACE1179. Investigations by the same author revealed that PrPc 
interacts directly with BACE1 since both are localised in cholesterol-rich, lipid 
rafts179-the site where β-secretase cleavage preferentially occurs180; 181. This 
interaction has been mapped to the BACE1 prodomain where it leads to slowed 
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BACE1 trafficking through the ER and trans-Golgi network, reducing BACE1 cell 
surface levels182. Hence it can be concluded that PrPc has a regulatory role in Aβ 
shedding, possibly protecting against AD183.  
 
Later, Vincent et al. described a link between PrPc and the catalytic subunit of γ-
secretase, the presenilins184. Within this study it was revealed that the AICD, resulting 
from the γ-secretase cleavage of APP, regulates the transcription of PrPc. It is believed 
that AICD, complexed to Tip60 and Fe65, translocates to the nucleus where it then 
acts as a transcription factor mediating the expression of p53184. p53, in turn, was 
shown to bind to the promoter region of PRNP, hence mediating PrPc expression184. 
Moreover, it has been noted that AICD acts as transcription factor for the Aβ-
degrading enzyme, neprilysin150; 185.  
 
The work of Parkin et al.179, taken together with that of Vincent et al.184 suggests that 
a possible feedback loop between AICD and PrPc might exist186 (Fig. 1.7). It is 
believed that β-secretase mediates the inhibition of AICD and Aβ by PrPc 186. In turn, 
the amount of amyloidogenic processing of APP regulates the inhibition of PrPc on 
BACE1 via the AICD, which regulates PrPc expression186. Such a feedback loop is 
thought to keep the physiological levels of Aβ in balance, ensuring sufficient amounts 
to maintain normal function while preventing toxic effects that are the result of Aβ 
accumulation186. However, in AD, the level of Aβ is elevated due to either its 
increased production and/or decreased clearance. This in turn results in the increased 
assembly of Aβ into soluble oligomers, which exerts their toxicity via the interaction 
with PrPc 186. The Aβ-PrPc interaction is believed to interfere with PrPc regulation of 
BACE1, which subsequently leads to the increased processing of APP and hence Aβ 
levels.  
 
Recently, however, through the use of transgenic mice, cell culture models and 
modulation of APP expression levels, no such link between PrPc expression and 
AICD regulation has been proven, suggesting that the control of PrPc levels by AICD 
is not as straightforward as originally proposed. Moreover, Calella et al. showed that 
altering the levels of PrPc, in APP/PS1 transgenic mice, does not change the levels of 
Aβ187. However, it is argued that the PS1 mutation used in this study might change the 
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metabolic pathway which results in Aβ formation, and hence the effectiveness of  
PrPc 188.   
 
Fig. 1.7| A possible feedback mechanism for the regulation of APP processing by PrPc. 
APP processing by β- and γ-secretase gives rise to sAPPβ, Aβ, and AICD (left). AICD forms 
a complex with Fe65 and Tip60, where it then translocates to the nucleus and interacts with 
the p53 promoter, regulating its expression. The p53 protein in turn acts a regulator of the 
PRNP gene for PrPc expression. PrPc is transported to lipid rafts within the cell membrane, 
where it is able to inhbit the action of the β-secretase, BACE1 (right). BACE1 inhibition 
results in decreased Aβ shedding and AICD release, hence downregulating the expression of 
PrPc (Adapted from 186). 
 
1.7.2. The prion protein as a receptor for amyloid-ß 
Evidence by Lauren et al.189 has elucidated to PrPc being the main receptor for Aβ 
oligomers, and responsible for mediating the neurotoxic effects of Aβ. Although Aβ 
oligomers are generally regarded as the pathogenic species responsible for AD-
associated neurodegeration48, the pathogenic mechanism activated by these oligomers 
remains unclear. Through binding studies, PrPc was identified as a high affinity 
receptor for soluble Aβ oligomers, while long-term potentiation (LTP) and behavioral 
studies (in vitro and in vivo, respectively) revealed that the absence of PrPc was able 
to prevent the toxic effects of Aβ oligomers189.  
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While a high affinity interaction between Aβ oligomers and PrPc has been confirmed, 
the role that this interaction plays in synaptic impairment has been excluded by 
several different studies188. Data obtained by Balducci et al.190 using PrP knockout 
mice revealed that although Aβ42 oligomers are the toxic species responsible for the 
AD pathogenicity, this effect occurs independently of PrPc. Likewise, two additional 
studies found that PrPc was not required for the impairment of synaptic plasticity by 
Aβ42 oligomers187; 191. While possible explanations have been put forward to explain 
these apparent contradictory results188, it becomes clear that the role of PrP in AD 
pathogenesis is still far from being fully elucidated36.  
 
1.8. Linking laminin and amyloid-β 
Laminin, an 850 kDa extracellular matrix, glycoprotein complex, has been found to 
interact with heparan sulfate proteoglycans192, heparin193 and collagen type IV194. 11 
isoforms of laminin has been identified, each composed of one of five different α-
chains (200-400kDa) joined to β (220kDa) and γ (210kDa) polypeptide chains to form 
a cruciform-like structure195. Functionally, laminin has been shown to be a powerful 
inducer of neurite outgrowths196; 197 and synapse formation198. Additionally, laminin 
production has been found to be stimulated in response to brain injury199 and 
specifically co-localises with Aβ deposits in AD and Down’s syndrome brains200. It 
has also been indicated that various isoforms of sAPPβ bind to laminin, as well as 
other basement membrane components201.  
 
Thioflavin T fluorescence spectroscopy and electron microscopic examination 
revealed that laminin inhibits Aβ fibrillation202. Castillo et al.203 later demonstrated 
that laminin not only binds Aβ with high affinity, but also acts as an inhibitor of Aβ 
fibrillogenesis. Within this same study, an Aβ binding site, located within the globular 
domain repeats on the laminin α chain, was identified203. In the presence of laminin, 
decreased amyloid neurotoxicity has been revealed in both rat primary hippocampal 
neurons and primary cortical cells204.  These studies have led to laminin being 
investigated as a possible target for the inhibition of Aβ fibrillogenesis, and ultimately 
AD pathogenesis.  
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1.9. The 37kDa/67kDa high affinity laminin receptor 
The 37kDa laminin receptor precursor (LRP) is believed to be the precursor of the 
67kDa high affinity laminin receptor (LR), however this relationship is poorly 
understood205. Direct homodimerisation of the 37kDa LRP seems to be an implausible 
argument based on the fact that LRP is monomeric and is not able to interact with 
itself, as determined by yeast-two hybrid analysis and size exclusion 
chromatography206. Additionally, it has been hypothesised that a mature 67kDa LR 
heterodimeric structure might be stabilised by fatty acid-mediated interactions, with 
additional analyses suggesting a role of acetylation in LRP processing to give rise to 
the mature receptor207; 208. Nonetheless, both the 37kDa LRP and 67kDa LR have 
been isolated from the cellular surface209. Given the above, it is often difficult to make 
a distinction between LRP and LR, and within this dissertation the receptor is 
generally referred to as LRP/LR. Knockdown of LRP, for example, will ultimately 
result in subsequent LR downregulation, and as such downstream effects observed 
from LRP knockdown cannot exclusively be put down to altered LRP levels but must 
include the contribution of LR. 
 
The LRP/LR is a non-integrin cell surface receptor that has been shown to have a high 
binding affinity for laminin, an extracellular matrix glycoprotein known to play a role 
in cell differentiation, movement, growth and attachment210; 211; 212; 213. The LRP/LR 
has two laminin binding domains located between amino acids 161-180 and 205-229 
214 (Fig. 1.8). Furthermore, the high affinity laminin receptor has been implicated in 
laminin-induced tumour proliferation, metastasis and invasiveness215; 216. The 
overexpression of the 67kDa LR- found in many cancer types- is correlated with both 
the invasiveness and metastatic potential of the tumour214; 217; 218. Anti-LRP/LR 
specific antibodies have been shown to interfere with adhesion and invasion, key 
events in metastatic cancer36; 205. In addition to its role as a high affinity receptor for 
laminin, the 67kDa LR has also been shown to act as a receptor for other extracellular 
matrix molecules including elastin and carbohydrates210. 
 
Moreover, LRP/LR has been shown to act as a receptor for both cellular and 
infectious prion proteins209; 219. Two LRP/LR binding domains have been identified 
on PrP, one direct and the other indirect, located between amino acids 144-179 and 
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53-93, respectively206. Binding of LRP/LR to the indirect binding domain is 
dependent upon the presence of heparan sulphate proteoglycans (HSPGs)206. HSPGs, 
consisting of core polypeptides to which glycosaminoglycans (GAGs) are covalently 
attached, have been shown to act as initial receptors for various extracellular 
molecules220; 221. Moreover, a direct PrP binding domain on the 37kDa/67kDa 
LRP/LR has been identified between amino acids 161-180206 (Fig. 1.8). While a 
HSPG-dependant binding site on LRP/LR has yet to be identified, one is assumed to 
be located between amino acids 180 and 285222. In relation to AD, HSPGs are known 
to be associated with Aβ deposits222. 
 
It has recently been demonstrated that LRP/LR acts as a receptor for the green tea 
extract, epigallocatechin-3-gallate (EGCG), inducing anti-cancer and anti-allergic 
activity within human colon cancer cells223. In another study, LRP/LR was implicated 
in tumour viability. It was shown that the down-regulation of LRP/LR via the use of 
siRNAs (in Hep3B cells) led to the promotion of apoptosis224. LRP/LR has also been 
shown to act as a receptor for a number of different viruses including the Dengue 
virus serotypes 1, 2 and 3225; 226, Sindbis virus227, Venezuelan equine encephalitis 
(VEE) virus228, and Adeno-associated virus (AAV) serotypes 2, 3, 8 and 9229. 
 
As mentioned above, the 37kDa/67kDa LRP/LR acts as a receptor on the cell surface. 
Furthermore, LRP/LR has been isolated from the cytoplasm and is associated in this 
subcellular compartment with the p40 ribosome and involved in 40S ribosomal 
subunit maturation230; 231. The 37kDa LRP has also been isolated from both the 
perinuclear compartment and nucleus, where it is in contact with PrP and histones, 
respectively230; 232; 233. The affinity between LRP and histones suggests a possible role 
for LRP in the maintenance of nuclear structures. Due to the fact that LRP/LR is 
found in various regions within the cells and has multiple functions, including a role 
in protein synthesis, cell viability and proliferation, the specific targeting of LRP/LR 
hold huge promise in the treatment of various human diseases.  
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Fig. 1.8| Schematic representation of the 37kDa laminin receptor precursor (LRP). The 
37kDa LRP is 295 amino acids (aa) in length and consists of four functional domains with its 
C-terminus exposed to the extracellular space. The transmembrane domain is located between 
amino acids 86-101, while a laminin/prion protein (PrP) binding domain has been found to be 
positioned between amino acids 161-180. Further, a heparin/laminin binding domain and a 
scFv/IgG1 antibody binding domain have been shown to be located at amino acid positions 
205-229 and 272-280, respectively. Four viruses are known to bind to LRP/LR, namely 
Venezuelan Equine Encephalitis Virus (VEE), Adeno-associated virus (AAV), Dengue virus 
and Sindbis virus. However, the binding domains of these aforementioned viruses to LRP/LR 
as of this time remains unclear, and as such viral-LRP binding has been arbitrarily depicted 
within this diagram (Adopted from 36). 
 
1.10. Implications of LRP/LR in Alzheimer’s disease 
LRP/LR has been reported to be a receptor for the basement membrane protein, 
laminin36. Additionally, it has been shown that laminin inhibits Aβ fibrillation202; 203. 
Moreover, Gauczynski et al. have shown that the 37kDa/67kDa LRP/LR acts as a 
receptor for both infectious (PrPSc) and non-infectious prions (PrPc)209; 219. It is known 
that PrPc inhibits Aβ shedding179, while also acting as a high affinity receptor for Aβ 
oligomers189. Thus, a possible relationship between LRP/LR (the receptor for PrPc/ 
PrPSc and laminin) and Aβ, whose shedding and fibrillation is regulated by PrPc and 
laminin, respectively, is conceivable.  
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1.11. RNA interference (RNAi)  
RNAi refers to the biological process by which a specific double-stranded RNA (ds-
RNA) sequence knockdowns the expression of a particular gene target234. This 
process was originally observed in plants235 but accurately described for the first time 
in Caenorhabditis elegans by Fire et al236. Shortly, the mechanism of RNAi involves 
the processing of the long ds-RNA into short or small interfering RNA (siRNA) by 
the endonuclease Dicer234 (Fig. 1.9). The processed siRNAs are approximately 21 
nucleotides in length, of which 19 nucleotides form a helix and 2 nucleotides on each 
of the 3’ ends are unpaired234. The ribonucleoprotein complex RISC (RNA-induced 
silencing complex) is then guided by the siRNA to its complementary mRNA target 
sequence234. The target mRNA is subsequently cleaved 10 nucleotides from the 5’ end 
of the siRNA strand237 by Argonaut 2 (Ago2) 238. The cleaved mRNA target lacks a 5’ 
end cap and 3’ poly-A tail that is endogenously responsible for mRNA stability, and 
as a result the cleaved mRNA is rapidly degraded by RNases and translation of the 
coded protein is inhibited. In mammalian cells, the loading of the siRNA into the 
RISC is achieved by the RISC-loading complex (RLC)- the constituents of which 
include Dicer and TAR RNA binding protein (TRBP)234. Moreover, during RISC 
activation, the passenger or sense strand is degraded while the guide or anti-sense 
strand incorporates into the RISC239; 240. 
 
The use of plasmids expressing short hairpin RNAs (shRNAs) is a useful system by 
which siRNAs are continuously generated in cells. In this system the shRNA is 
converted into DNA sequences coding for a sense-strand, loop region and anti-sense 
strand234. The DNA template is designed to be transcribed from a vector under the 
control of the RNA polymerase III promoter (usually U6 or H1 promoter). During 
transcription, a self-complementary RNA is synthesized, referred to as an shRNA234. 
The resultant shRNA is processed by Dicer to form a siRNA, which mediates gene 
silencing as described above.  
 
The ability of RNAi to modulate gene expression has dramatically enhanced the study 
of gene function, in addition to revolutionizing disease treatment. Inherent difficulties 
in blocking several desirable targets through the use of small molecule inhibitors or 
monoclonal antibodies for example, has led to the explosion of interest into RNAi-
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based therapies241. Despite its attractiveness as an alternative therapeutic approach for 
the treatment of numerous diseases, several hurdles must be overcome to successfully 
introduce RNAi-based therapies into the clinical setting. Some of which include a safe 
and efficient delivery system and avoidance of off target effects241. 
 
 
Fig. 1.9| RNAi mechanism. Subsequent to uptake of siRNAs into the mammalian cell, the 
siRNAs are loaded onto RISC by RLC. During this process, the sense strand is degraded. The 
anti-sense strand guides RISC to its complementary target RNA where Ago2 induces targeted 
cleavage of the mRNA. RNAi can also be accomplished through the intracellular expression 
of shRNA in a similar mechanism as described above (Adapted from 234). 
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1.12. Aims and Objectives 
1.12.1. Aim 
The aim of this research was to ascertain a possible role of LRP/LR in the proteolytic 
processing of APP and hence shedding of Aβ. 
 
1.12.2. Objectives 
i. Assess the cellular distribution of the AD relevant proteins, namely APP, β- 
and γ-secretases in relation to LRP/LR using indirect immunofluorescence 
microscopy  
ii. Determine, by enzyme-linked immunosorbent assay (ELISA), whether the 
shRNA-mediated downregulation of LRP/LR will significantly reduce the 
shedding of Aβ 
iii. Determine the molecular mechanism underlying the possible reduction in Aβ 
shedding. That is, to determine the role of LRP/LR in APP processing, and 
specifically with β- and γ-secretase via: 
a. The shRNA-mediated downregulation of LRP/LR and Western blot 
detection for sAPPβ  
b. The determination of the cell surface levels of APP, β- and γ-secretase 
using flow cytometry on shRNA-treated cells  
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CHAPTER 2 
 
2. Materials and Methods 
 
2.1.Short hairpin ribonucleic acid (shRNA) production 
2.1.1. shRNA design 
Prof. M. Weinberg (Department of Internal Medicine, University of the 
Witwatersrand) assisted with the design of shRNA constructs targeting human LRP 
mRNA (Appendix 1.1). The shRNA constructs were produced together with a fellow 
MSc student of the laboratory, Kiashanee Moodley. The target sequence for LRP-
shRNA1 was identified based on the bioinformatic prediction tool, ‘The RNAi 
Consortium’ (http://www.broadinstitute.org/rnai/). LRP-shRNA7 and LRP-shRNA9 
target sequences are the human homologues of the murine target sequences for 
pENTR siRNA-LRP7 and pENTR siRNA-LRP9, respectively242 (Appendix 1.2). 
LRP-shRNA1, 7 and 9 were designed to be Polymerase Chain Reaction (PCR) 
amplified in two separate rounds using the H1 RNA Polymerase III promoter (pTI-
H1, kindly donated by Prof. M. Weinberg) as a template, such that the complete 
expression cassette included a full length H1 promoter sequence. Further, cassettes 
were designed with the siRNA guide strand in the 3’ arm of the shRNA and to include 
a ploy-T termination signal. The oligonucleotides used as the forwards and reverse 
primers were produced by Integrated DNA Technologies. A randomized/scrambled 
control (pTZ57R/T shRNAscr) that does not target any gene product was used as a 
negative control and kindly donated by Prof. M. Weinberg.  
 
2.1.2. Nested PCR 
First round of PCR 
In a sterile, nuclease-free PCR tube the following was combined on ice: 10µl 5X Go 
Taq® Reaction buffer (Promega), 1µl deoxyrhibonucleotide triphosphate (dNTP) mix-
10mM each (Promega), 0.25µl GoTaq® DNA Polymerase-5u/µl (Promega), 5µl 
25mM MgCl2 (Promega), 50pg pTI-H1 (template DNA), 0.5µM H1 F + XbaI 
(forward primer), 0.5µM reverse primer (see below), and nuclease-free water to a 
final volume of 50µl.  Primers used were as follows: 
Forward primer:  
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H1 F + XbaI  
5’ GATCTCTAGAGCGAACGCTGACGTCATCAA 3’ 
Reverse primer:  
LRP-shRNA1 R1 
5’CCATTTGGGTCAGGAATGGCAACAATTGCACGAGCGGGTCCGAGTGGTC
TCATAC3’ 
or 
LRP-shRNA4 R1 
5’CTTCCTGGGTCAGGAGAAGGCTGCCTGGATCTGGCGGGTCCGAGTGGTC
TCATAC3’ 
or 
LRP-shRNA7 R1 
5’GAATTTGGGTCAGGAATTCCTCCTTGGTCACTGCCGGGTCCGAGTGGTCT
CATAC3’ 
 
The reactions were placed in a thermal cycler (Biometra trio-thermoblockTM), 
preheated to 95°C. The thermal cycling conditions included an initial denaturation 
step at 95°C for 3 min, followed by 32 cycles of denaturation at 95°C for 30 sec; 
annealing at 60°C for 30 sec; and extension at 72°C for 30 sec, with a final extension 
cycle at 72°C for 15 min. The first round of PCR products were visualized by 
electrophoresis (Cleaver scientific CS-300V) at 100V for approx. 45min on a 1% 
agarose gel (Appendix 1.3.1).  
 
Second round of PCR 
In a sterile, nuclease-free PCR tube the following was combined on ice: 10µl 5X Go 
Taq® Reaction buffer (Promega), 1µl deoxyrhibonucleotide triphosphate (dNTP) mix-
10mM each (Promega), 0.25µl GoTaq® DNA Polymerase-5u/µl (Promega), 5µl 
25mM MgCl2 (Promega), 1µl PCR product from the first round of PCR (template 
DNA), 0.5µM H1 F + XbaI (forward primer), 0.5µM reverse primer (see below), and 
nuclease-free water to a final volume of 50µl.  Primers used were as follows: 
Forward primer: see above 
Reverse primer: 
LRP-shRNA1 R2 
5’ AAAAAAGCTCGTGCAATTGTTGCCATTTGGGTCAGGAATG 3’ 
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or 
LRP-shRNA4 R2 
5’ AAAAAAGCCAGATCCAGGCAGCCTTCCTGGGTCAGGAGAA 3’ 
or 
LRP-shRNA7 R2 
5’ AAAAAAGGCAGTGACCAAGGAGGAATTTGGGTCAGGAATT 3’ 
 
Thermal cycle conditions were as previously documented above. The second round of 
PCR products were visualized by electrophoresis (Cleaver scientific CS-300V) at 
100V for approx. 45min on a 1% agarose gel (Appendix 1.3.1). 
 
2.1.3. PCR Clean-up 
The Wizard® SV Gel and PCR Clean-up System (Promega) was used to remove 
excess nucleotides and primers from the PCR products prior to ligation. This system 
is designed to extract and purify DNA fragments from standard agarose gels in either 
Tris acetate (TAE) or Tris borate (TBE). PCR products were separated by 
electrophoresis on a 1% agarose gel as previously described (see 3.1.2). A 1.5ml 
microcentrifuge tube for each PCR product to be isolated was weighed. The PCR 
product was excised in a minimal volume of agarose using a clean scalpel. The gel 
slice was transferred to the weighed microcentrifuge tube and the weight recorded. 
Membrane binding solution was added to the tube at a ratio of 10µg of solution per 
10mg of agarose gel slice. The mixture was vortexed and incubated at 60°C for 
approximately 10min (or until the gel slice was completely dissolved). One SV 
Minicoloumn was placed in a collection tube for each dissolved gel slice. The 
dissolved gel mixture was transferred to the SV Minicolumn assembly and incubated 
at room temperature for 1min. The SV Minicolumn assembly was centrifuged at 
16 000g for 1min (Eppendorf 5417C), followed by removal of the liquid in the 
collection tube. The column was washed by addition of 700µl Membrane Wash 
solution to the SV Minicolumn assembly and centrifuged at 16 000g for 1min 
(Eppendorf 5417C). The collection tube was emptied and the SV Minicolumn re-
washed with 500µl Membrane Wash solution. The SV Minicolum assembly was 
centrifuged at 16 000g for 5min. The liquid from the collection tube was removed and 
the SV Minicolumn assembly re-centrifuged at 16 000g for 1min. The SV 
Minicoulmn was transferred to a clean 1.5ml microcentrifuge tube. 50µl of nuclease-
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free water was added directly to the centre of the column without touching the 
membrane with the pipette tip. The system was incubated at room temperature for 
1min and then centrifuged at 16 000g for 1min. The microcentrifuge tube containing 
the eluted DNA was stored at -20°C.  
 
2.1.4. Ligation reaction 
The cleaned product of the second round of PCR (see 3.1.3) was ligated into the 
pTZ57R/T plasmid using the InsTAcloneTM PCR Cloning Kit (Fermentas). The 
ligation reaction was set up by combining the following components in a sterile 
microcentrifuge tube: 3µl vector pTZ57R/T (0.17pmol ends) (Fermentas), 6µl 5X 
ligation buffer (Fermentas), 68.5ng PCR product (0.52pmol ends), nuclease-free 
water to a final volume of 29µl and 1µl T4 DNA liagse (Fermentas). The mixture was 
mixed and incubated overnight at 4°C.   
 
2.1.5. Preparation of competent bacteria 
Preparation of competent Escherichia coli (E.coli) XL-1blue was achieved using the 
TransformAidTM Bacterial Transformation kit supplied as part of the InsTAcloneTM 
PCR Cloning kit (Fermentas). The day before transformation, an overnight culture 
was seeded by inoculating 2ml of C-medium (Fermentas) with a single colony of 
E.coli XL-1blue. The culture was incubated overnight at 37°C with shaking at 
200r.p.m (Labcon SPL15). The day of transformation, 1.5ml C-medium was pre-
warmed to 37°C for 20min. 150µl of the overnight bacterial culture was added to 
1.5ml warmed C-medium. The mixture was incubated for 20min at 37°C with shaking 
at 180r.p.m. The bacterial cells were pelleted by centrifugation for 1min at 3300g 
(Eppendorf 5417C). The supernatant was discarded and the cells resuspended in 
300µl T-solution (Appendix 1.5.1) followed by incubation on ice for 5min. The 
mixture was centrifuged for 1min at 3300g, the supernatant discarded and the cell 
pellet resuspended in 120µl T-solution followed by incubation on ice for 5min.  
 
2.1.6. Transformation 
2.5µl of the ligation mixture (see 3.1.4) was placed in a microcentrifuge tube and 
chilled on ice for 2min. 50µl of the prepared E.coli XL-1blue (see 3.1.5) was added to 
the DNA-containing tube, mixed and incubated on ice for 5min. The mixture was 
plated onto pre-warmed LB-plates containing 50µg/ml ampicillin, 0.1mM IPTG and 
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40µg/ml X-Gal (Appendix 1.6.4) and incubated overnight at 37°C for blue/white 
screening. 
 
2.1.7. Plasmid purification: mini-prep 
4-6 white colonies were individually inoculated into 5ml LB medium (Appendix 
1.5.2) containing 50µg/ml ampicillin. The cultures were grown at 37°C for 16h with 
constant shaking at 200r.p.m (Labcon SPL15). Plasmids were isolated using the 
NucleoSpin® Plasmid DNA Purification kit (Macherey-Nagel) according to the 
following protocol. 5ml of the saturated E.coli LB culture was centrifuged at room 
temperature for 30sec at 11 000g (Eppendorf 5417C). The supernatant was discarded 
and the cells resuspened in 250µl Buffer A1. 250µl Buffer A2 was added to the cell 
suspension, gently mixed by inverting the tube 6-8 times and incubated at room 
temperature for 5min. 300µl Buffer A3 was added to the tube and mixed thoroughly 
by inverting 6-8 times. Following centrifugation at room temperature for 5min at 
11 000g, the supernatant was placed within a NucleoSpin® Plasmid Column in a 2ml 
Collection Tube. The column/tube was centrifuged for 1min at 11 000g. The flow-
through was discarded and the column placed back into the collection tube. The silica 
membrane was washed with 600µl Buffer A4, followed by centrifugation for 1min at 
11 000g. The flow-through was discarded and the column placed back into the 
collection tube. The silica membrane was dried by centrifugation for 2min at 11 000g. 
The column was placed in a 1.5ml microcentrifuge tube and 50µl Buffer AE added. 
Subsequent to an incubation period of 1min at room temperature, the plasmid DNA 
was eluted by centrifugation for 1min at 11 000g. The final DNA concentration in the 
sample was quantified with the Nanodrop® ND-1000 Spectrophotometer.  
 
2.1.8. Plasmid DNA sequencing 
The inserts of the isolated plasmid DNA (pTZ57R/T LRP-shRNA1, pTZ57R/T LRP-
shRNA7 and pTZ57R/T LRP-shRNA9) were sequenced using standard M13/pUC 
sequencing primers by Inqaba biotec.  
 
2.2.Cell lines 
The Neuro-2a (or N2a) cell line is derived from the neuroblastoma of a strain A 
albino mouse and supplied by the American Type Culture Collection (ATCC). The 
cell line was cultured in 10cm tissue culture dishes (Corning) and maintained in a 
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humidified, 37°C, 5% carbon dioxide atmosphere. N2a cells were cultured in Opti-
MEM Reduced Serum Medium (Gibco®) supplemented with 10% Foetal Calf Serum 
(FCS) (PAA Laboratories) and 1% Penicillin-Streptomycin antibiotic mixture 
(Gibco®). Sub-confluent cultures (70-80%) were split 1:10 to 1:20. 
 
The human neuroblastoma cell line, SH-SY5Y, is a thrice-cloned sub-line of bone 
marrow biopsy-derived line SK-N-SH and was obtained from the European 
Collection of Cell Cultures (ECACC). The cell line was cultured in 10cm tissue 
culture dishes (Corning) and maintained in a humidified, 37°C, 5% carbon dioxide 
atmosphere. SH-SY5Y cells were maintained in F12 Nutrient Mixture: Eagles 
Minimal Essential Media (1:1) (Gibco®) supplemented with 2mM Glutamine 
(Gibco®), 1% Non-Essential Amino Acids (NEAA) (Gibco®), 15% FCS and 1% 
Penicillin-Streptomycin antibiotic mixture. Sub-confluent cultures (70-80%) were slit 
1:10. 
 
The HEK293 cell line is derived from human embryonic kidney cells transformed 
with adenovirus 5 DNA and was originally supplied by ATCC. Cell lines were 
cultured in 10cm tissue culture dishes (Corning) and maintained in a humidified, 
37°C, 5% carbon dioxide atmosphere. HEK293 cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) (Gibco®) supplemented with 10% FCS and 1% 
Penicillin-Streptomycin antibiotic mixture. Subculivation of 70-80% confluent cells 
occurred at a ratio of 1:10 to 1:20. 
 
 
The subculturing procedure for the above mentioned cell lines are as follows: the 
culture medium was aspirated and the monolayer of cells rinsed with Dulbecco’s 
Phosphate-buffered saline (D-PBS) (Gibco®). 1ml of 0.25% (w/v) Trypsin- 0.53mM 
ethylenediaminetetra-acetic acid (EDTA) solution (Gibco®) was added to the cell 
culture dish and incubated at 37°C for approximately 5min (or until the cell layer was 
dispersed when viewed under an inverted microscope). The cells were resuspended in 
9ml of the appropriate complete growth medium (see above). Aliquots of the cell 
suspension were added to new culture vessels, while subcultivation occurred at the 
ratios listed above.  
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2.3.Plasmids 
For the downregulation of LRP mRNA levels in murine cells (N2a), the following 
plasmid contructs were employed: pENTR siRNA-LRP4, pENTR siRNA-LRP7 and 
pENTR siRNA-LRP9242 (Appendix 1.2). It is important to note that although the 
aforementioned plasmids are designated as siRNA constructs, they are in fact shRNA 
constructs.  pTZ57R/T LRP-shRNA1 and pTZ57R/T LRP-shRNA7 (see 3.1) (also 
referred to as LRP-shRNA1 and LRP-shRNA7) were used to downregulate LRP 
mRNA levels in the human cell line, HEK293. pTZ57R/T shRNAscr (also referred to 
as LRP-shRNAscr) does not target any gene product and was used as a negative 
control. pCIneo-GFP, a plasmid encoding the Green Fluorescent Protein (GFP) was 
used to assess the transfectability of HEK293 and N2a cells (see 3.7.1, 3.7.2 and 
3.8.1).  Both pTZ57R/T shRNAscr and pCIneo-GFP were kindly donated by Prof. M. 
Weinberg.  
 
2.4.Preparation of competent bacteria for heat-shock transformation 
A colony of E.coli XL-1blue cells was inoculated into 2ml LB medium (Appendix 
1.5.2) and incubated at 37°C overnight with shaking at 180r.p.m (Labcon SPL15). 
1ml of the overnight culture was inoculated into 100ml LB medium (Appendix 1.5.2) 
and incubated at 37°C and 180r.p.m (Labcon SPL15) to an OD600 value of 
approximately 0.5. The culture was chilled on ice for 15min and centrifuged for 
10min at 3300g at 4°C (Heraeus sepatech RF). The supernantant was discarded and 
the cells resuspended in 30ml ice cold 0.1MCaCl2, followed by incubation on ice for 
30min. The cells were centrifuged for 10min at 3300g at 4°C. The supernatant was 
removed and the cell pellet resuspended in 6ml ice cold 0.1M CaCl2/15% glycerol 
solution. 50µl of the cell suspension was aliquoted into sterile 1.5ml microcentrifuge 
tubes, rapidly frozen in liquid nitrogen (10sec) and stored at -70°C.  
 
2.5.Heat-shock transformation 
The competent XL-1blue E.coli cells prepared above (see 3.4) were thawed on ice for 
approximately 5min. 100ng of plasmid DNA (see 3.3) was added to 50µl of the 
competent cells in a sterile microcentrifuge tube. The contents were mixed, placed on 
ice for 30min, and heat-shocked at 42°C for 45sec. The tube was placed back on ice 
for 2min and 900µl of pre-warmed SOC medium (37°C) (Appenidx 1.6.6) was added 
to the mixture. The contents were incubated at 37°C for 60min with shaking at 
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220r.p.m (Labcon SPL15). 100µl of pENTR siRNA-LRP4, pENTR siRNA-LRP7 and 
pENTR siRNA-LRP9 transformation mixtures were inoculated onto LB-plates 
containing 50µg/ml kanomycin (Appendix 1.6.7), which were incubated overnight at 
4°C. 100µl of the pTZ57R/T LRP-shRNA1, pTZ57R/T LRP-shRNA7, pTZ57R/T 
shRNAscr and pCIneo-GFP transformation mixtures were inoculated onto LB-plates 
containing 50µg/ml ampicillin (Appendix 1.6.3), which were incubated overnight at 
37°C.  
 
2.6. Plasmid purification: Maxi-prep 
The endotoxin-free plasmid DNA purification kit, NucleoBond® Xtra Maxi Plus EF 
(Macherey-Nagel), was used to extract sufficient amounts (up to 500µg) of purified 
plasmid from transformed competent bacteria. A starter culture was prepared by 
inoculating 5ml of LB medium containing the appropriate selective antibiotic with a 
single colony picked from the transformed bacterial plate. The following plasmids 
were grown in LB medium (Appendix 1.5.2) containing 50µg/ml kanomycin: pENTR 
siRNA-LRP4, pENTR siRNA-LRP7 and pENTR siRNA-LRP9. pTZ57R/T LRP-
shRNA1, pTZ57R/T LRP-shRNA7, pTZ57R/T shRNAscr and pCIneo-GFP were 
grown in LB medium (Appendix 1.5.2) containing 50µg/ml ampicillin. The starter 
cultures were incubated at 37°C for 8h with shaking at 300r.p.m (Labcon SPL15). A 
large overnight culture was prepared by diluting the starter culture 1:1000 into 300ml 
of LB medium containing the appropriate selective antibiotic. Cultures were grown at 
37°C for approximately 16h at 300r.p.m until an OD600 of 4 was reached. The cells 
were pelleted by centrifugation at 4°C for 10min at 6 000g (Heraeus sepatech RF). 
The supernatant was discarded  and the cell pellet resuspended in 12ml Resuspension 
Buffer RES-EF + RNase A. 12ml Lysis Buffer LYS-EF was added to the suspension 
and the tube gently mixed by inverting 5 times. The mixture was incubated at room 
temperature for 5min. 12ml Neuralisation Buffer NEU-EF was added to the 
suspension and the lysate mixed by inverting the tube 10-15 times, followed by 
incubation on ice for 5min. The NucleoBond® Xtra Column together with the inserted 
column filter was equilibrated with 35ml Equilibration Buffer EQU-EF and allowed 
to empty by gravity flow. The lysate was applied to the equilibrated NucleoBond® 
Xtra Column Filter and allowed to empty by gravity flow. The NucleoBond® Xtra 
Column and Filter was washed with 10ml Filter Wash Buffer FIL-EF. The column 
filter was discarded and the NucleoBond® Xtra Column washed with 90ml Wash 
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Buffer ENDO-EF. The column was washed a third time with 45ml Wash Buffer 
WASH-EF and the plasmid DNA eluted with 15ml Elution Buffer EF.  
 
The plasmid DNA was concentrated with the NucleoBond® Finalizer (supplied as part 
of the NucleoBond® Xtra Maxi Plus EF kit (Macherey-Nagel)) according to the 
following protocol: The DNA was precipitated with 0.7 volumes of isoporpanol, 
followed by vortexing and incubation at room temperature for 2min. The plunger 
from a 30ml syringe was removed and the NucleoBond® Finalizer attached to the 
outlet. The precipitation mixture was filled into the syringe, the plunger reinserted and 
the mixture slowly pressed through the finalizer. The NucleoBond® Finalizer was 
washed with 5ml 70% ethanol and the filter membrane of the finalizer dried by 
pressing through air using the syringe and plunger. The finalizer was attached to the 
outlet of a 1ml syringe and 500µl of Redissolving Buffer TE-EF added to the syringe. 
The plasmid DNA was eluted from the finalizer by inserting the plunger into the 
syringe. The first eluate was transferred back into the syringe and passed a second 
time through the finalizer. The DNA yield was quantified with the Nanodrop® ND-
1000 Spectrophotometer.  
 
2.7.Transient transfections 
2.7.1. HEK293 cells 
In order to assess the transfectability of HEK293 cells using TransIT®-LT1 
Transfection Reagent (Mirus), the cells were transfected with pCIneo-GFP followed 
by immunofluorescence microscopy. The day before transfection, 3x105 HEK293 
cells were seeded in complete growth medium (see 3.2) onto a microscope slide 
within each well of a 6-well plate (Corning). The cell cultures were incubated 
overnight in a humidified, 37°C, 5% carbon dioxide atmosphere. On the day of 
transfection, the complete growth medium was replaced by 2.5ml antibiotic-free 
complete growth medium. 250µl of serum-free DMEM (Gibco®) was placed in a 
sterile microcentrifuge tube to which 7.5µl of TransIT®-LT1 Transfection Reagent 
(pre-warmed to room temperature) was added. 2.5µg plasmid DNA was added to the 
diluted TransIT-LT1 Reagent, the solution mixed and incubated at room temperature 
for 30min. The TransIT-LT1 Reagent-DNA complex was added dropwise to the cells 
and the culture vessel rocked back and forth and from side to side to evenly distribute 
the TransIT-LT1 Reagent-DNA complexes. Cells were incubated in a humidified, 
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37°C, 5% carbon dioxide atmosphere for 24h prior to slide preparation for 
immunofluorescence.  
 
In order to downregulate the LRP mRNA levels in HEK293 cells, cells were 
transfected with pTZ57R/T LRP-shRNA1, pTZ57R/T LRP-shRNA7 and pTZ57R/T 
shRNAscr (control) using TransIT®-LT1 Transfection Reagent (Mirus). The day 
before transfection, 3x105 HEK293 cells were seeded in 2.5ml complete growth 
medium (see 3.2) in each well of a 6-well plate (Corning). Transfection was carried 
out as detailed above, however, a transfection incubation period of 72h (as opposed to 
24h) was allowed prior to analysis.   
 
2.7.2. N2a cells 
In order to assess the transfectability of N2a cells using GenePORTER® 2 
Transfection Reagent: QuikEaseTM Single-Use Tubes (Genlantis), the cells were 
transfected with pCIneo-GFP followed by immunofluorescence microscopy. The day 
before transfection, 6x105 cells were seeded in antibiotic-free complete growth 
medium (see 3.2) onto a microscope coverslip within each well of a 6-well plate 
(Corning). 4µg of plasmid DNA was diluted with 100µg DNA Diluent and incubated 
at room temperature for 5min. Serum-free Opti-MEM Reduced Serum Medium 
(Gibco®) was added to the diluted DNA to a final volume of 250µl. The Gene 
PORTER 2 reagent was hydrated with the DNA solution, pipetted up and down 5 
times and incubated at room temperature for 20min. The GenePORTER 2/DNA 
complexes were added directly to the N2a cells growing in 750µl antibiotic-free 
complete growth medium. The culture vessels were incubated in a humidified, 37°C, 
5% carbon dioxide atmosphere for 24h prior to slide preparation for 
immunofluorescence. 
 
In order to downregulate the LRP mRNA levels in N2a cells, cells were transfected 
with pENTR siRNA-LRP4, pENTR siRNA-LRP7, pENTR siRNA-LRP9 and 
pTZ57R/T shRNAscr (control) using GenePORTER® 2 Transfection Reagent: 
QuikEaseTM Single-Use Tubes (Genlantis). The day before transfection, 6x105 N2a 
cells were seeded in antibiotic-free complete growth medium (see 3.2) in each well of 
a 6-well plate (Corning). Transfection was carried out as detailed above, however, a 
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transfection incubation period of 72h (as opposed to 24h) was allowed prior to 
analysis.   
 
2.7.3. SH-SY5Y cells 
Thermo Scientific Dharmacon® Accell® siRNA Reagents is specially modified for use 
without a transfection reagent and works at a higher concentration than conventional 
siRNA with minimal disruption of the expression profile. When used with Accell® 
siRNA® delivery media, little to no delivery optimization is required. This system is 
particularly useful for difficult-to-transfect cell lines such as SH-SY5Y cells 243. 
Accell® siRNA®-human LAMR1 (Thermo Scientific Dharmacon), targeting a single 
open reading frame of the LRP sequence, together with Accell® siRNA® Delivery 
media (Thermo Scientific Dharmacon) was used to downregulate LRP/LR expression 
levels in SH-SY5Y cells.  
 
The day before transfection, 3.3x105 SH-SY5Y cells were plated in complete growth 
medium (see 3.2) in each well of a 6 well plate (Corning). On the day of transfection, 
5x siRNA buffer (Thermo Scientific Dharmacon®) was diluted to 1x siRNA buffer 
with RNase-free water (Thermo Scientific). 100µM siRNA®-human LAMR1 solution 
(Thermo Scientific Dharmacon) in 1x siRNA buffer was prepared and stored in 
aliquots at -20°C until use. In a separate sterile microcentrifuge tube, 20µl of 100µM 
siRNA solution was mixed with 1980µl Accell® siRNA® Delivery media (Thermo 
Scientific Dharmacon) to a final concentration of 1µM. The growth media from the 
cells was removed and replaced with the Accell siRNA-delivery media mixture. The 
cells were incubated in a humidified, 37°C, 5% carbon dioxide atmosphere for 72h.  
 
2.8.Immunofluorescence microscopy 
2.8.1. Transfectability of HEK293 and N2a cells 
HEK293 and N2a cells transfected with pCIneo-GFP (see 3.7.1 and 3.7.2, 
respectively) were tested for their transfectability with their respective transfection 
reagents. The microscope coverslips onto which the cells were grown and transfected, 
were fixed in 4% paraformaldedye (Appendix 1.7.1) for 15min. The cells were rinsed 
four times in PBS (Appendix 1.7.2), blocked and permeabilised in 0.25% Triton X-
100 + 0.5% Bovine serum albumin (BSA) solution (Appendix 1.7.4) for 10min, 
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followed by an additional wash in PBS. 100µl of a 1:100 dilution of Hoechst 33342 
stain (2mg/ml, Sigma-Aldrich) in PBS was prepared and placed onto the coverslip for 
10min. The cells were rinsed in PBS and mounted onto a clean microscope slide with 
50µl Fluoromount™ Aqueous Mounting Medium (Sigma-Aldrich). The prepared 
slides were allowed to dry for at least 1h in the dark and subsequently stored at 4°C 
until ready to be viewed. Cells were visualised using the Olympus IX71 
Immunofluorescence Microscope and AnalySIS getIT Software. (Hoechst: λex = 
346nm, λem = 460nm; GFP: λex = 488 nm, λem = 509nm). 
2.8.2. Indirect immunofluorescence microscopy 
Indirect immunofluorescence microscopy was employed to assess the cellular 
distribution of APP, β- and γ-secretase in relation to LRP/LR on the cell surface. 
HEK293 cells were cultured on microscope coverslips placed within the wells of a 
six-well plate (Corning). Following incubation in a humidified, 37°C, 5% carbon 
dioxide atmosphere for 24 hours, cells were fixed in 4% paraformaldehyde (Appendix 
1.7.1) at room temperature for 15min. Cultures were rinsed four times in PBS 
(Appendix 1.7.2), blocked in 0.5% BSA solution (Appendix 1.7.3) for 10min, 
followed by an additional wash in PBS. 100µl of the primary antibody diluted 1:150 
in 0.5% BSA solution (Appendix 1.7.3) was placed on the coverslip and incubated 
overnight at 4°C. LRP/LR was detected with IgG1-iS18 (Affimed Therapeutics). APP 
was detected with anti-APP (rabbit polyclonal IgG) (Abcam). β-secretase was 
detected using anti-BACE (M-83) (rabbit polyclonal IgG) (Santa Cruz 
Biotechnology). γ-secretase was detected by anti-PEN-2 (FL-101) (rabbit polyclonal 
IgG) (Santa Cruz Biotechnology). VLA6 (negative control) was detected by anti-very 
late antigen-6 (VLA6) CD49-f (rabbit monoclonal IgG) (Immunotech). Following 
incubation in primary antibody, the cells were rinsed three times in 0.5% BSA 
solution. 100µl of the appropriate secondary antibody diluted 1:350 in 0.5% BSA 
solution, was added to the cells and incubated in the dark at room temperature for 
60min. VLA6, APP, β- and γ-secretase were indirectly labelled with Alexa Fluor® 
633 (Life TechnologiesTM) , while an anti-human fluorescein isothiocyanate (FITC) 
coupled antibody (Cell Lab) was used to label LRP/LR. The cultures were rinsed 
three times in PBS and mounted onto clean microscope slides with 50µl 
Fluoromount™ Aqueous Mounting Medium (Sigma-Aldrich). The prepared slides 
were allowed to dry for at least 60min in the dark and subsequently stored at 4°C until 
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ready to be viewed. Cells were visualised using the Olympus IX71 
Immunofluorescence Microscope and AnalySIS getIT Software. 2D-cytofluorograms 
were acquired using CellSens Software. (Alexa Fluor® 633: λex = 633nm, λem = 
647nm; FITC: λex = 494 nm, λem = 518nm). 
 
2.9.Cell lysate preparation 
Following the transfection of HEK293, N2a and SH-SY5Y cells (see 3.7), the culture 
medium was aspirated and the cells rinsed in D-PBS (Gibco®). 100µl of lysis buffer 
(Appendix 1.8.1) was added to the cells that were subsequently scraped from the 
culture dish and added to a microcentrifuge tube. The cell lysates were incubated on 
ice for 15min, followed by centrifugation for 2min at 20 000g (Eppendorf 5417C). 
The supernatant was collected, transferred to a new microcentrifuge tube and stored at 
-20°C.   
 
2.10. Protein quantification 
The bicinchoninic acid (BCA) assay is based upon the reduction of Cu2+ ions in the 
presence of peptides, with the amount of Cu1+ being formed directly proportional to 
the concentration of protein. The bicinchoninic acid chelates the Cu1+, forming a deep 
purple complex that absorbs light at a wavelength of 562nm. 0, 0.2, 0.4, 0.6, 0.8 and 
1mg/ml BSA standards were prepared and 25µl of each of the BSA-standards were 
added to a 96 well plate (Corning). 1:5 dilutions of crude cell lysates (see 3.9) were 
prepared and added to the plate. 200µl of BCA reagent (Sigma-Aldrich) (Appendix 
1.9.1) was added to the wells containing the BCA standards and diluted cell lysates. 
The plate was incubated at 37°C for 30min and the absorbance measured at 562nm 
(Tecan Sunrise Microtitre plate).  
 
2.11. Immunoblot analysis 
LRP/LR levels within the crude cell lysate of HEK293, N2a and SH-SY5Y 
transfected cells were determined by Western blot analysis. Additionally, the 
shedding of sAPPβ within the cell culture medium of transfected HEK293 cells was 
investigated by the same methodology. The crude cell lysate/cell culture medium was 
mixed with 5x Laemmli sample buffer (Appendix 1.10.1) and denatured by heating at 
95°C for 5min. 30µg of protein per lane (for LRP/LR detection) and 220µg of protein 
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per lane (for sAPPβ detection) was resolved on a 12% SDS-PAGE gel (Appendix 
1.10.2) according to Laemmli244 at constant voltage (200V) with electrophoresis 
buffer (Appendix 1.10.3) (Biorad Mini PROTEAN® Tetra cell and PowerPacTM HC). 
Samples were electroblotted onto polyvinylidene fluoride (PVDF) transfer membrane 
(PALL Life Sciences), using the PerfectBlue `semi-dry` electro blotter 52-2020 
(PeQLab) at 350mA for 45min in Western blot transfer buffer (Appendix 1.11.1).  
The membrane was blocked in blocking buffer (Appendix 1.11.3) for 60min and 
incubated with either IgG1-iS18 (1: 5000, for the detection of LRP/LR) (Affimed 
Therapeutics) or anti-sAPPβ-wild type (1:1000) (Immuno-Biological Laboratories) 
diluted in blocking buffer, overnight at 4°C. Washing was performed three times at 
10min intervals with PBS-Tween (Appendix 1.11.2).  The membrane was incubated 
in a horse-radish peroxidase (HRP) coupled secondary antibody diluted 1:10 000 in 
blocking buffer for 60min (Rabbit anti-human IgG-HRP (Santa Cruz Biotechnology) 
for LRP/LR; goat anti-rabbit IgG-HRP (CellLab) for sAPPβ detection). Following 
incubation in the appropriate secondary antibody, membranes were washed six times 
at 5min intervals with PBS-Tween, before being exposed to the SuperSignal West 
Pico Chemiluminescent Substrate kit: working solution (Pearce) (Appendix 1.11.4). 
Blots were sealed in polyethylene wrap and exposed to CL-X PosureTM Film (Thermo 
Scientific) for 10min. The film was developed using GBX developer and replenisher 
(Kodak), briefly rinsed in water, before being fixed in GBX fixer and replenisher 
(Kodak). The film was rinsed in water before being allowed to dry. The GS-800TM 
Calibrated Densitometer (Biorad) and Quantity One 1D Analysis Software (Biorad) 
was used for densitometric analysis of western blots.  
 
2.12. Enzyme-Linked Immunosorbent Assay (ELISA) 
Human Amyloid β(1-x) Assay kit (Immuno-Biological Laboratories) was used to 
assess the concentration of Aβ shed within the cell culture medium of transfected 
HEK293 cells. The assay was performed as per manufacturer’s instructions. Shortly, 
human Aβ(1-40) standard solutions containing 0.00, 7.81, 15.63, 31.25, 62.50, 
125.00, 250.00 and 500.00pg/ml were prepared. 100µl of each of the standards and 
transfected HEK293 cell culture medium was added to the wells of the ELISA plate 
and incubated overnight at 4°C. Each well was washed seven times with wash buffer, 
before adding 100µl of labeled antibody and incubating at 4°C for 60min. The wells 
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were washed an additional nine times with wash buffer and 100µl of chromagen 
solution was added. After an incubation period of 30min at room temperature in the 
dark, the absorbance was measured at 450nm (Tecan Sunrise Microtitre plate).  
 
2.13. Flow cytometry 
Flow cytometry was used to assess the cell surface levels of APP, β- and γ-secretase 
on HEK293 cells subsequent to shRNA treatment. The medium from transfected 
HEK293 cells was aspirated and the cells rinsed with D-PBS (Gibco®).  300µl of 
0.25% (w/v) Trypsin- 0.53mM EDTA solution (Gibco®) was added to the cell culture 
dish and incubated at 37°C for approximately 5min (or until the cell layer was 
dispersed when viewed under an inverted microscope). The detached cells were 
resuspended in 2ml of HEK293 complete cell culture medium (see 3.2), transferred to 
15ml centrifuge tube, and centrifuged at 4°C for 10min at 120g (Heraeus sepatech 
RF). The supernatant was discarded and the cells resuspended in 1ml 4% 
paraformaldehyde (Appendix 1.7.1).  The mixture was transferred to a 
microcentrifuge tube and incubated at 4°C for 10min. The cells were centrifuged at 
4°C for 10min at 1700g (Eppendorf 5417C) and the cell pellet resuspended in 1ml 
EPICSTM Sheath Fluid (Beackman Coulter). 500µl of the cell suspension was 
transferred to a microcentrifuge tube. Both tubes were centrifuged at 4°C for 10min at 
1700g, the supernatant discarded and the cell pellet resuspended in 100µl of either 
30µg/ml primary antibody solution or EPICSTM Sheath Fluid (control). After an 
incubation period of 60min at room temperature, the cells were washed three times 
with 200µl EPICSTM Sheath Fluid, followed by centrifugation at 4°C for 1min at 
2000g in between each wash. 100µl of 20µg/ml FITC-coupled secondary antibody 
was added to both microcentrifuge tubes and allowed to incubate at room temperature 
for 60min in the dark. Cells were washed three times with 200µl EPICSTM Sheath 
Fluid, followed by centrifugation at 4°C for 1min at 2000g in between each wash. The 
cell pellets were resuspended in 1ml EPICSTM Sheath Fluid before analysis on the 
Accuri C6 flow cytometer (BD Bioscience).  
 
Cell surface APP levels were ascertained using an anti-APP (rabbit polyclonal IgG) 
(Abcam)!and the corresponding goat anti-rabbit FITC secondary antibody. β-secretase 
levels were detected using anti-BACE (M-83) (rabbit polyclonal IgG) (Santa Cruz 
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Biotechnology)!and goat anti-rabbit FITC secondary antibody (Cell labs). γ-secretase 
levels on the surface of the cells were detected by a primary antibody directed against 
the PEN-2 subunit of the γ-secretase complex (anti-PEN-2 (FL-101) (rabbit 
polyclonal IgG) (Santa Cruz Biotechnology)), and the corresponding goat anti-rabbit 
FITC secondary antibody.  
 
2.14 Statistical analysis and Pearson’s correlation co-efficient 
Statistical analyses were performed using a two-tailed student’s t-test with a 95% 
confidence interval (GraphPad Prism 5). p-values less than 0.05 were considered 
significant. The Pearson’s correlation coefficient between LRP downregulation and 
decrease in Aβ shedding was calculated using the WolframAlpha Pearson’s 
correlation coefficient calculator 
(http://www.wolframalpha.com/widgets/view.jsp?id=3038cb5ccf72f21a13801d9c78f70937). 
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CHAPTER 3 
 
3. Results 
 
3.1 Production of LRP-shRNA targeting human LRP mRNA 
Nested PCR was employed to amplify LRP-shRNA1, LRP-shRNA4 and LRP-
shRNA7 oligonucleotides. Bands at 300bp (Fig. 4.1a) and 350bp (Fig. 4.1b) represent 
the PCR products from the first and second round of PCR, respectively. LRP-
shRNA1, LRP-shRNA4 and LRP-shRNA7 amplified products from the second round 
of PCR were ligated into the pTZ57R/T plasmid and subsequently transformed into 
E.coli XL-1Blue. Cultures were plated onto LB-plates containing 50µg/ml ampicillin, 
0.1mM IPTG and 40µg/ml X-Gal. Successful ligation and transformation was 
confirmed by the presence of blue and white colonies for LRP-shRNA1 (Fig. 4.2a), 
LRP-shRNA4 (Fig. 4.2b) and LRP-shRNA7 (Fig. 4.2c). Individual white colonies 
from each plate were inoculated into LB medium containing 50µg/ml ampicillin and 
the plasmids isolated. Sequencing of plasmids was performed to ensure integrity of 
the desired sequences and to check for the directionality of the PCR insert. 
Sequencing results for LRP-shRNA4 displayed several errors with regards to the 
expected nucleotide code. Due to the high specificity of RNAi, a single nucleotide 
mismatch can serve as a negative control245 and as such subsequent experimentation 
was performed using only LRP-shRNA1 and LRP-shRNA7.  
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Fig. 3.1| PCR amplified LRP-shRNA oligonucleotides from (a) first round of PCR and 
(b) second round of PCR. The amplified products from the first and second round of PCR 
were resolved on a 1% agarose gel. Bands at 300bp and 350bp, respectively, represent the 
primary and secondary PCR products of LRP-shRNA1, -4 and -7.  
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Fig. 3.2| E.coli XL-1Blue transformed with (a) LRP-shRNA1, (b) LRP-shRNA4 and (c) LRP-shRNA7. LRP-shRNA1, -4 and -7 PCR amplified products 
were ligated into the pTZ57R/T plasmid and subsequently transformed into competent E.coli XL-1blue for blue-white screening. Cultures were plated onto 
LB-plates containing 50µg/ml ampicillin, 0.1mM IPTG and 40µg/ml X-Gal.  
 
 
  
a) c) b) 
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3.2 HEK293 cells are transfectable using TransIT®-LT1 Transfection Reagent 
HEK293 cells were transfected with either pCIneo-GFP (Fig. 4.3a-c) or mock 
transfected (without any plasmid) (Fig. 4.3 d-f) using TransIT®-LT1 Transfection 
Reagent. 24h post transfection, cells were fixed and their nuclei stained with Hoechst 
33342. GFP expression of pCIneo-GFP transfected cells is evident (Fig. 4.3a), 
indicative of the transfectability of HEK293 cells using TransIT®-LT1 Transfection 
Reagent. Absence of GFP expression is noted in the mock-transfected control cells 
(Fig. 4.3d).  Since green fluorescence was observed surrounding the nuclei of each 
cell, the transfection efficiency of the HEK293 cells was concluded to be 100%.  
 
 
3.3 N2a cells are transfectable using GenePORTER® 2 Transfection Reagent 
N2a cells were transfected with either pCIneo-GFP (Fig. 4.4a-c) or mock transfected 
(without any plasmid) (Fig. 4.4d-f) using GenePORTER® 2 Transfection Reagent. 
24h post transfection, cells were fixed and their nuclei stained with Hoechst 33342. 
GFP expression of pCIneo-GFP transfected cells is evident (Fig. 4.4a), indicative of 
the transfectability of N2a cells using GenePORTER® 2 Transfection Reagent. 
Absence of GFP expression is noted in the mock-transfected control cells (Fig. 4.4d).  
Since green fluorescence was observed surrounding the nuclei of each cell, the 
transfection efficiency of the N2a cells was concluded to be 100%. 
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Fig. 3.3| Immunofluorescence microscopy images of HEK293 cells transfected using TransIT®-LT1 Transfection Reagent. HEK293 cells were 
transfected with (a-c) pCIneo-GFP or (d-f) mock transfected (without a plasmid) using TransIT®-LT1 Transfection Reagent. 24h post-transfection, cells were 
fixed and the nuclei stained with Hoechst 33342. (a) Green fluorescent protein (GFP) expression was observed in pCIneo-GFP transfected cells, but not in the 
mock-transfected control (d). (b, e) Hoechst-stained nuclei.  (c, f) Merges between GFP and Hoechst-stained nuclei. Images were obtained using the Olympus 
IX71 Immunofluorescence Microscope and AnalySIS getIT Software. Hoechst: λex = 346nm, λem = 460nm; GFP: λex = 488 nm, λem = 509nm. Magnification 
1000x.  
GFP Hoechst Merge 
a) 
d) 
c) b) 
f) e) 
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Fig. 3.4| Immunofluorescence microscopy images of N2a cells transfected using GenePORTER® 2 Transfection Reagent. N2a cells were transfected 
with (a-c) pCIneo-GFP or (d-f) mock transfected (without a plasmid) using GenePORTER® 2 Transfection Reagent. 24h post-transfection, cells were fixed 
and the nuclei stained with Hoechst 33342. (a) Green fluorescent protein (GFP) expression was observed in pCIneo-GFP transfected cells, but not in the 
mock-transfected control (d). (b, e) Hoechst-stained nuclei.  (c, f) Merges between GFP and Hoechst-stained nuclei. Images were obtained using the Olympus 
IX71 Immunofluorescence Microscope and AnalySIS getIT Software. Hoechst: λex = 346nm, λem = 460nm; GFP: λex = 488 nm, λem = 509nm. Magnification 
1000x. 
GFP Merge Hoechst 
a) 
f) e) d) 
c) b) 
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3.4 LRP-shRNA treatment of HEK293 cells significantly decreases LRP 
expression levels 
HEK293 cells were transfected with LRP-shRNA1, LRP-shRNA7 and LRP-shRNAscr. 
72h post-transfection, cells were lysed and LRP levels assessed by Western blotting. 
Bands at 37kDa are indicative of LRP (Fig. 4.5a). β-actin, observed at 42kDa, was used 
as a loading control (Fig. 4.5a). Western blot band intensities from three independent 
experiments revealed a significant decrease in LRP expression. LRP-shRNA1 and LRP-
shRNA7 treated HEK293 cells resulted in a 42.85% and 16.42% reduction in LRP levels, 
respectively, when compared to the scrambled control (LRP-shRNAscr) (Fig. 4.5b).   
 
 
3.5 pENTR siRNA-LRP treatment of N2a cells does not significantly 
downregulate LRP expression 
N2a cells were transfected with pENTR siRNA-LRP4, pENTR siRNA-LRP7, pENTR 
siRNA-LRP9 and LRP-shRNAscr. 72h post-transfection, cells were lysed and LRP 
expression assessed by immunoblotting. Bands at 37kDa are representative of the 37kDa 
LRP (Fig. 4.6a). β-actin, seen at 42kDa, was used as a loading control (Fig. 4.6a). 
Densitometric analysis from three independent experiments does not reveal a significant 
change in LRP expression levels in pENTR siRNA-LRP treated N2a cells (compared to 
the LRP-shRNAscr control) (Fig. 4.6b).  
 
 
3.6 siRNA-LAMR1 treatment of SH-SY5Y cells does not significantly alter LRP 
levels 
SH-SY5Y cells were either transfected with siRNA-LAMR1 or mock-transfected 
(without any siRNA). 72h post-transfection, cells were lysed and LRP levels assessed by 
Western blotting. Bands at 37kDa are indicative of LRP (Fig. 4.7a). The β-actin loading 
control is seen at 42kDa (Fig. 4.7a). Immunoblot banding intensities from three 
independent experiments does not show a significant change in LRP levels in siRNA-
LAMR1 treated SH-SY5Y cells (as compared to the mock-transfected control) (Fig. 
4.7b).   
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Fig. 3.5| Effect of shRNA treatment on LRP levels in HEK293 cells. (a) HEK293 cells were 
transfected with LRP-shRNA1, LRP-shRNA7 and LRP-shRNAscr. 72h post-transfection, cells 
were lysed and LRP levels assessed by Western blotting. β-actin was used as a loading control. 
(b) Western blot band intensities from three independent experiments were quantified using 
Quanity One 4.5.2 software. Results shown are expressed as percentage changes compared to 
control levels. *p<0.05, **p<0.01, Student’s t-test.  
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Fig. 3.6| Effect of pENTR siRNA-LRP treatment on LRP levels in N2a cells. (a) N2a cells 
were transfected with pENTR siRNA-LRP4, pENTR siRNA-LRP7 and pENTR siRNA-LRP9 (as 
well as a scrambled control, LRP-shRNAscr). 72h post-transfection, cells were lysed and LRP 
levels assessed by Western blotting. β-actin was used as a loading control. (b) Western blot band 
intensities from three independent experiments were quantified using Quanity One 4.5.2 software. 
Results shown are expressed as percentage changes compared to control levels. p>0.05, Student’s 
t-test.  
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Fig. 3.7| Effect of siRNA-LAMR1 treatment on LRP levels in SH-SY5Y cells. (a) SH-SY5Y 
cells were either transfected with siRNA-LAMR1 or mock transfected. 72h post-transfection, 
cells were lysed and LRP levels assessed by Western blotting. β-actin was used as a loading 
control. (b) Western blot band intensities from three independent experiments were quantified 
using Quanity One 4.5.2 software. Results shown are expressed as percentage changes compared 
to control levels. p>0.05, Student’s t-test.  
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3.7 LRP-shRNA treatment of HEK293 cells significantly decreases Aβ  shedding 
To investigate whether LRP/LR is involved in the amyloidogenic pathway and more 
specifically Aβ shedding into the extracellular space, HEK293 cells were transfected with 
LRP-shRNA1, LRP-shRNA7 and the scrambled control, LRP-shRNAscr. 72h post-
transfection, the Aβ concentration of the cell culture medium of the transfected cells was 
analysed using an Aβ ELISA. A 42.85% and 16.42% decrease in LRP expression levels, 
correlated to a significant 16.88% and 11.95% reduction in Aβ shedding in HEK293 cells 
(for LRP-shRNA1 and LRP-shRNA7, respectively) (Fig. 4.8a). No significant difference 
in Aβ concentration was observed in LRP-shRNAscr and mock-transfected HEK293 
cells (Fig. 4.8b).  
 
3.8 There is a strong positive correlation between LRP downregulation and 
reduced Aβ  shedding 
The Pearson’s correlation co-efficient was calculated as a measure of the strength of the 
relationship between LRP knockdown and decreased Aβ shedding. A Pearson’s 
correlation coefficient value of 1 was obtained between said variables, indicating that 
there is a strong positive correlation between LRP downregulation and reduced Aβ 
shedding.  
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Fig 3.8| Aβ  concentration of the cell culture medium of LRP-shRNA transfected HEK293 
cells. (a) HEK293 cells were transfected with LRP-shRNA1, LRP-shRNA7 and the 
scrambled control, LRP-shRNAscr (b) HEK293 cells were either transfected with the 
scrambled control or mock-transfected with no plasmid. 72h post- transfection, the Aβ 
concentration of the cell culture medium was analysed using an Aβ ELISA. n=3, 
*p<0.05, **p<0.01, Student’s t-test. 
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3.9 LRP-shRNA treatment of HEK293 cells does not alter cell surface expression 
of APP, β-secretase and γ-secretase 
In order to determine whether LRP/LR influences the amyloidogenic pathway through 
alteration of cell surface expression levels of the AD relevant proteins, flow cytometry 
was employed. HEK293 cells were either transfected with LRP-shRNA1, LRP-shRNA7, 
LRP-shRNAscr or mock-transfected without a plasmid. The difference in fluorescence 
(shift to the right in the flow cytometry histogram overlay plots) of the APP, β-secretase 
and γ-secretase stained LRP-shRNA-transfected cells relative to that of unstained, mock-
transfected control cells reflects the number of HEK293 cells that possessed the 
aforementioned AD relevant proteins on the cell surface (Fig. 4.9a). Over 99% of all 
HEK293 cells analysed (for LRP-shRNA1, LRP-shRNA7 and LRP-shRNAscr) revealed 
APP, β-secretase and γ-secretase on their cell surface (Fig. 4.9a and b).  Analysis of three 
independent experiments showed that LRP-shRNA1 and LRP-shRNA7 treated HEK293 
cells did not significantly alter cell surface levels of APP, β-secretase and γ-secretase 
(compared to the LRP-shRNAscr control) (Fig. 4.9b). 
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Fig. 3.9| Analysis of APP, β-secretase and γ-secretase levels on the surface of shRNA treated 
HEK293 cells by flow cytometry. HEK293 cells were transfected with LRP-shRNA1, LRP-
shRNA7 and LRP-shRNAscr. 72 hours post transfection, the cell surface levels of APP, β- and γ-
secretase were ascertained by flow cytometry (BD Accuri C6). (a) Flow cytometry histogram 
overlay plots. Images shown are a representative of 3 independent experiments. (b) Bar chart of 
cell surface levels of the AD related proteins. n=3, p>0.05, Student’s t-test.  
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3.10 sAPPβ  levels are significantly decreased by LRP-shRNA treatment of 
HEK293 cells 
In an attempt to elucidate the mechanism by which LRP/LR influences the 
amyloidogenic pathway, sAPPβ levels of the cell culture medium of LRP-shRNA 
transfected HEK293 cells was analysed by Western blotting. Bands at 110kDa are 
representative of sAPPβ (Fig. 4.10a). In the absence of a specific and well-accepted 
protein loading control for secreted proteins, equal loadings were justified by taking 
equal volumes of cell culture medium from the same number of cells grown under 
identical conditions246. A 22.66% significant reduction in sAPPβ levels was observed in 
LRP-shRNA1 treated HEK293 cells (compared to the control, LRP-shRNAscr) (Fig. 
4.10b). Although a mean reduction of 14.87% in sAPPβ expression was noted in LRP-
shRNA7 treated HEK293 cells, this change was deemed non-significant due to large 
error bars obtained (Fig. 4.10b).  
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a) 
 
 
 
b) 
 
 
Fig. 3.10| sAPPβ  levels of the cell culture medium of LRP-shRNA transfected HE293 cells. 
(a) HEK293 cells were transfected with LRP-shRNA1, LRP-shRNA7 and the scrambled control, 
LRP-shRNAscr. 72h post- transfection, sAPPβ levels of the cell culture medium was analysed by 
Western blotting. (b) Western blot band intensities from three independent experiments were 
quantified using Quanity One 4.5.2 software. Results shown are expressed as percentage changes 
compared to control levels. ***p<0.001, Student’s t-test. 
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3.11 LRP/LR co-localises with APP, β-secretase and γ-secretase on the surface of 
HEK293 cells 
Indirect immunofluorescence microscopy was employed to assess the cellular distribution 
of LRP/LR in relation to the AD relevant proteins APP, β-secretase and γ-secretase. 
Indirect immunofluorescence microscopy requires the analysis of two colour images (red 
and green in this instance) for the presence of an overlapping or co-localisation signal. A 
high degree of co-localisation indicates close proximity of the two-labeled proteins, and 
therefore suggests an interaction between them247. LRP/LR was shown to co-localise with 
APP (Fig. 4.11a i-iv), β-secretase (Fig. 4.11a v-viii) and γ-secretase (Fig. 4.11a ix-xii) on 
the surface of non-permeabilised HEK293 cells, as represented by the yellow merged 
images (Fig. 4.11 iii, vii, xi) and 2D-cytofluorograms (Fig. 4.11a iv, viii, xii). The 2D-
cytofluorograms show the joint distribution of the red and green fluorescence, with a 
yellow diagonal confirming co-localisation between the proteins of interest. An alternate 
laminin binding receptor, VLA6, was employed as a negative control and failed to co-
localise with LRP/LR (as previously observed by 248) (Fig. 4.11a xiii-xvi, Table. 4.1). 
Further, Pearson’s correlation co-efficients for co-localisation between LRP/LR and the 
AD relevant proteins are given (Table 4.1). Pearson’s co-efficient is not a true 
quantification of co-localisation but rather an estimate of the strength of association 
between two proteins. A Pearson’s co-efficient value of 1 is indicative of full correlation, 
while a value of zero is indicative of the absence of correlation249. The Pearson’s co-
efficient values obtained for LRP/LR with APP, β-secretase and γ-secretase were 0.862, 
0.915 and 0.938, respectively, representative of a strong correlation between said proteins 
and thereby confirming co-localisation results obtained above. 
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Fig. 3.11| Co-localisation between LRP/LR and the AD relevant proteins on the surface of 
HEK293 cells. HEK293 cells were indirectly immunolabelled for detection using the Olympus 
IX71 Immunofluorescence Microscope and AnalySIS getIT Software. (i) APP (detected by anti-
APP). (v) β-secretase (detected using anti-BACE (M-83). (ix) γ-secretase (detected by anti-PEN-2 
(FL-101). (xiii) VLA6, a negative control (detected by anti-very late antigen-6 (VLA6) CD49-f). 
APP, β-secretase, γ-secretase and VLA6 were indirectly labelled with Alexa Fluor® 633, while an 
anti-human FITC conjugated antibody was used to label LRP/LR (ii, vi, x, xiv). The merges 
between LRP/LR and AD relevant proteins are shown (iii, vii, xi, xv) and the corresponding 2D-
cytofluorograms (acquired using CellSens Software) have been included to confirm the degree of 
co-localisation (iv, viii, xii, xvi). Alexa Fluor® 633: λex = 633nm, λem = 647nm; FITC: λex = 
494 nm, λem 
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Table 3.1| Pearson’s correlation co-efficient of co-localisation between LRP/LR and the AD 
relevant proteins on the surface of HEK293 cells 
! Pearson’s!correlation!co.efficient!
LRP/LR!+!APP! 0.862&
LRP/LR!+!β .secretase! 0.915&
LRP/LR!+!γ .secretase! 0.938&
LRP/LR!+!VLA6! 0.583&
* Pearson’s correlation co-efficient for LRP/LR and the AD related proteins, APP, β-secretase 
and γ-secretase (as well as VLA6, the negative control). A Pearson’s correlation co-efficient 
value of 1 indicates complete co-localisation, while 0 is indicative of no co-localisation.  
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CHAPTER 4 
 
4. Discussion  
 
4.1 Failure of LRP downregulation in SH-SY5Y and N2a cells by siRNAs/shRNAs 
directed against LRP mRNA 
Transfection of SH-SY5Y and N2a cells with siRNA-LAMR1 and pENTRsiRNA-LRP4, 
7 and 9, respectively, failed to result in significant LRP knockdown. Lipid-based 
transfection and electroporation are widely used and well-validated techniques for 
transfection of many standard cell lines. Such methods have often proved ineffective for 
cell types that are typically refractory to standard lipid-based delivery. Neuronal cells, 
including N2a and SH-SY5Y cells are such examples250. Accell siRNA (Dharmacon) 
offers the advantage of enabling transfection into difficult-to-transfect cell types without 
the need for transfection reagents, viral vector or instruments.  Accell siRNA has been 
shown to be effective in SH-SY5Y cells251, albeit with an alternate gene target to the one 
used in this dissertation. A single siRNA targeting the LRP gene (siRNA-LAMR1) was 
selected for use in SH-SY5Y cells; however, a mixture of four siRNA (provided as a 
single reagent, SMARTpool (Dharmacon)) would provide advantages in both potency 
and efficacy of gene knockdown. Gene knockdown can be determined by both mRNA 
and protein knockdown. In this study, protein levels were assessed by Western blotting. 
Perhaps a more sensitive technique for detecting gene silencing, and one that could be 
used in future studies, is quantitative real time PCR (QRT-PCR)250. While this technique 
is often perceived as quick and reliable, QRT-PCR is not an established technique within 
our laboratory and can suffer from poor reproducibility and variability250.  
 
As previously mentioned, N2a cells, like other neuronal cell lines are notoriously difficult 
to transfect250.  However, downregulation of LRP was previously achieved in scrapie 
infected neuronal cells (ScN2a) using pENTR siRNA-LRP4, pENTR siRNA-LRP7 and 
pENTR siRNA-LRP9, respectively252. Endogenous LRP levels were decreased by 50%, 
47% and 54% for pENTR siRNA-LRP4, pENTR siRNA-LRP7 and pENTR siRNA-
LRP9, respectively (in comparison to the control). Similar results could not be achieved 
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in N2a cells using the same plasmids and transfection regent in neither this study nor one 
from a previous student of the laboratory (unpublished data 253). The transfectability of 
N2a cells using GenePORTER® 2 Transfection reagent was confirmed and could not 
provide a possible explanation for the variance in LRP downregulation. Transfection 
efficiencies of up to 100% in N2a cells using GenePORTER® 2 Transfection reagent 
have been previously reported253. Further, plasmids were sequenced and their nucleotide 
sequence confirmed, eliminating point mutations within the plasmid as a potential 
explanation for the observed lack of LRP downregulation. The difference in cell lines 
(scrapie infected N2a cells compared to N2a cells) could provide a potential explanation 
as to the apparent ineffectivity of the pENTR siRNA-LRP constructs. In addition, the 
effect of passage number on cell line transfection must be considered. It has been 
demonstrated that although low and high passage cells can be transfected equally well, 
protein expression in high-passage cells is significantly altered compared to low passage 
cells254; 255. Higher passage N2a cells were used in this study and could provide an 
alternate explanation as to the inconsistent transfection performance observed.  !
 
4.2 Factors affecting the knockdown of LRP expression in HEK293 cells 
A number of factors can influence the degree of gene knockdown induced by RNAi and 
include i) transfection efficiency, ii) transcription rate of the gene of interest, iii) protein 
stability, iv) efficacy of the siRNA sequence chosen and v) growth characteristics of the 
cell line245. Transfectability of HEK293 cells using TransIT®-LT1 Transfection Reagent has 
been proved (Fig. 4.3). Given an siRNA target alone, it is not possible to predict the degree 
of gene knockdown produced 245. Further, not all siRNAs directed against a target gene 
are equally effective in suppressing expression of that target gene245. Publicly available 
siRNA design programs typically show success rates of approximately 50% in generating 
siRNAs that yield over 70% silencing effects (www.ambion.com/RNAi). LRP-shRNA1 
and LRP-shRNA7 achieved 42.85% and 16.42% knockdown of LRP compared to the 
scrambled control (Fig. 4.5). In order to achieve higher levels of gene knockdown, 
several more siRNA targets would need to be evaluated.  
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4.3 LRP-shRNA treatment of HEK293 cells significantly decreases Aβ  shedding 
A 42.85% and 16.42% decrease in LRP expression in HEK293 cells, correlated to a 
significant 16.88% and 11.95% reduction in Aβ shedding, respectively. These results are 
the first of its kind to implicate LRP/LR in the amyloidogenic processing of APP and 
specifically Aβ shedding, pointing to an alternate therapeutic route for the treatment of 
AD. It would be interesting to investigate the maximum reduction in Aβ shedding 
attainable through LRP knockdown. However, as stated above, more effective LRP-
shRNA targets would need to be investigated in order to achieve LRP knockdown in the 
range of >90%.  
 
 
4.4 There is a strong positive correlation between LRP downregulation and 
reduced Aβ  shedding 
The Person’s correlation coefficient between LRP knockdown and decreased Aβ 
shedding was calculated to have a value of 1, thus implying that a strong positive 
correlation between said variable exists. This result further suggests that LRP 
downregulation and its associated decrease in Aβ shedding could be exploited as an 
alternative therapeutic route to hamper Aβ shedding and subsequent plaque formation in 
AD.   
 
 
4.5 LRP-shRNA treatment of HEK293 cells does not alter cell surface expression 
of APP, β-secretase and γ-secetase 
The cell surface levels of APP, β- and γ-secretase were investigated to allude to a 
possible mechanism by which LRP knockdown impedes Aβ shedding. Interestingly, LRP 
downregulation and accompanying hindrance of Aβ shedding did not alter the cell 
surface expression levels of APP, β-secretase and γ-secretase. That is, the proteins central 
to the amyloidogenic pathway remained unaffected by a decrease in LRP expression. 
Thus, the influence of LRP/LR could potentially be as a result of protein interaction. 
Involvement of LRP/LR in the amyloidogenic pathway is therefore believed to be 
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independent of gene expression modulation and most likely to involve an interaction (be 
it direct or indirect) with APP, β-secretase or γ-secretase.  This idea is further supported 
by the co-localisation of LRP/LR with APP, β-secretase and γ-secretase on the surface of 
HEK293 cells. While co-localisation is not explicitly indicative of an interaction between 
the proteins of interest, it does imply that a possible protein interaction between LRP/LR 
and the AD related proteins does exist (co-localisation of LRP/LR with APP, β-secretase 
and γ-secretase is discussed further under section 4.7). Further studies investigating this 
interaction, through the use of pull-down assays and fluorescence resonance energy 
transfer (FRET) for example (see 5.10), would provide valuable insight into the exact 
mechanism by which LRP/LR influences the amyloidogenic pathway.  
 
 
4.6 sAPPβ  levels are significantly decreased by LRP-shRNA treatment of 
HEK293 cells 
The mechanism by which LRP/LR knockdown impedes Aβ shedding was further 
investigated through the determination of sAPPβ levels in the cell culture medium of 
shRNA-treated HEK293 cells. sAPPβ is the initial cleavage product of APP by β-
secretase and as such sAPPβ expression levels are an indirect measure of β-secretase 
activity. Knockdown of LRP levels resulted in a significant decrease in sAPPβ 
expression, suggesting that downregulation of LRP impedes sAPPβ shedding into the 
extracellular space. These results implicate LRP/LR in the amyloidogenic processing of 
APP, and specifically via augmenting the activity of β-secretase.  
 
A significant decrease in sAPPβ expression was only observed as a result of LRP-
shRNA1-treatment. Although a mean reduction of 14.87% in sAPPβ expression was 
noted in LRP-shRNA7 treated HEK293 cells, this change was deemed non-significant 
due to the large errors attained. Additional experimental repeats would potentially reduce 
the variability obtained for triplicate value and result in significant data. 
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The sequential cleavage of APP by β- and γ-secretase are essential for Aβ production, 
with enhanced activity of either enzyme resulting in increased Aβ shedding and hence 
plaque formation. The influence of LRP/LR on β-secretase activity has been investigated 
and clearly implicates LRP/LR in the amyloidogenic pathway through enhanced β-
secretase cleavage of APP. Whether, LRP/LR augments the shedding of Aβ through 
altered γ-secretase activity still needs to be investigated. The contribution of LRP/LR on 
γ-secretase activity (through the determination of AICD expression) and its potential 
influence on Aβ shedding cannot as this time be investigated due to the fact that the 
AICD has eluded detection in cell and tissue lysates, often being regarded as a non-
significant by-product of APP processing that is rapidly degraded256. An antigen retrieval 
protocol has recently been employed to detected endogenous AICD by Western blotting; 
however this technique has only been proved effective for brain tissue samples 256.  
 
 
4.7 LRP/LR co-localises with APP, β-secretase and γ-secretase on the surface of 
HEK293 cells 
LRP/LR was shown to co-localise with the AD relevant proteins APP, β-secretase and γ-
secretase on the surface of HEK293. The Pearson’s correlation co-efficients, although not 
a true quantification of co-localisation, do provide an estimate of the strength of 
association between the proteins of interest249. Taken together, the immunofluorescence 
images and Pearson’s correlation coefficients, allude to a spatial overlap between said 
proteins on the cell surface. Although these results are not explicitly indicative of an 
interaction between LRP/LR and APP, β-secretase and γ-secretase, they do imply that a 
non-random association between LRP/LR and the AD relevant proteins exist. Such use of 
co-localisation studies as a preliminary indication of protein interaction has been widely 
used 257. Further studies to confirm an interaction between LRP/LR and the AD related 
proteins may include pull-down assays, FRET and live cell imaging (see 5.9). 
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4.8 Role of LRP/LR in the amyloidogenic processing of APP 
The fact that LRP/LR co-localises with β-secretase on the cell surface, taken together 
with LRP/LR’s ability to promote β-secretase activity, has led us to propose a direct 
interaction between LRP/LR and β-secretase. This interaction would appear to enhance 
the amyloidogenic processing of APP and hence shedding of Aβ. Further studies 
validating this interaction would obviously be required to prove this hypothesis.  
 
As mentioned above (see 5.6), the contribution of γ-secretase on the proteolytic 
processing of APP has not been investigated within this study for various reasons. Co-
localisation of LRP/LR with γ-secretase does imply that an interaction between said 
proteins exists and it hypothesized that the influence of LRP on Aβ shedding may further 
be augmented by enhanced γ-secretase activity either through a direct or indirect 
interaction of said proteins. Co-localisation of LRP/LR with APP, through further 
investigation, may prove to be an important binding partner involved in the 
amyloidogenic pathway, with an interaction possibly enhancing β-secretase/γ-secretase 
activity or both.  
 
Alternatively, the observed effects of LRP on the amyloidogenic pathway are potentially 
through a more indirect route. As LRP/LR is the receptor for PrPC 209, a knockdown of 
LRP/LR would result in an increased concentration of freely available PrPC on the cell 
surface. PrPC has been shown to negatively regulate β-secretase activity and hence Aβ 
shedding 179. Thus we postulate that the effects observed upon shRNA treatment could 
potentially be as a result of more freely available PrPC on the cell surface to hamper β-
secretase activity. As this is the first investigation implicating LRP/LR in the 
amyloidogenic processing of APP, there are still many unknowns with regards to the 
mechanism by which LRP/LR influences Aβ shedding. Further studies will provide 
valuable insight as to the role of LRP/LR in the proteolytic processing of APP and hence 
contribution to AD.  
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4.9 Conclusions 
A novel role of LRP/LR in AD and more specifically in the amyloidogenic processing of 
APP has been identified. Downregulation of LRP though the use of shRNA resulted in a 
decrease in both sAPPβ and Aβ shedding within the extracellular space. LRP-shRNA 
treatment has been proposed to exert its effect through inhibiting the activity of β-
secretase rather than modulating gene expression of APP, β-secretase and γ-secretase. 
Further, LRP/LR has been shown to co-localise with the AD relevant proteins APP, β-
secretase and γ-secretase on the cell surface, alluding to a possible interaction between 
said proteins. Owing to LRP/LR’s influence in APP processing and Aβ shedding 
specifically, shRNAs targeted against LRP mRNA could potentially be used as 
alternative therapeutic tools for the treatment of AD.  
 
4.10 Outlook 
The exact mechanism by which LRP/LR influences APP processing still needs to be 
investigated. Confocal microscopy and specifically z-stacks (which permits one to obtain 
images of planes at various depths within the sample) will be employed to determine the 
exact subcellular localisation of LRP/LR in relation to APP, β- and γ-secretase. Pull-
down assays between LRP/LR and the AD related proteins will provide valuable 
information on whether a physical interaction between LRP/LR and APP, β- and γ-
secretase exists. Fluorescence resonance energy transfer (FRET) describes the distance-
dependent interaction between the electronic excited states of two chromophores 
(fluorescently tagged LRP/LR and either APP, β-secretase or γ-secretase) in which 
excitation is transferred from a donor molecule to an acceptor molecule without emission 
of a photon. When FRET is used as a contrast mechanism, co-localisation of proteins can 
be imaged with spatial resolution beyond the limits of conventional microscopy. FRET 
will be employed to determine the co-localisation and hence possible interaction between 
LRP/LR and the AD-related proteins. Further, live cell imaging will be used to track the 
movement and possible interaction between fluorescently labeled LRP/LR and the AD-
related proteins. This technique will provide more detailed information as to the cellular 
dynamics involved in the aforementioned interactions. Since shRNAs directed against 
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LRP mRNA were able to significantly decrease Aβ shedding in vitro, its effect in vivo 
warrants investigation. Before transitioning into in vivo studies, the mechanism by which 
LRP/LR exerts its effects in APP processing must be fully elucidated.  
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APPENDIX 
 
1.1 LRP-shRNA1, 7 and 9 design 
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1.2 pENTRsiRNA-LRP4, 7 and 9 target sequences !
 
 
 
 
1.3 Electrophoresis: Agarose gel 
 
1.3.1 Agarose gel (1%) 
0.7g Agarose 
Make up to 70ml with 1X TBE buffer 
Heat until agarose dissolves 
Add 5µl ethidium bromide 
Pour gel and allow to set 
 
1.3.2 TBE buffer (10X), pH8.3 
890mM Tris 
890mM  Boric acid 
20mM  EDTA  
Adjust pH to 8.3 
Make up to a final volume of 1000ml with dH2O 
 
  
Supplementary Fig. S1. mRNA sequence of the murine laminin receptor precursor. Target RNA sequences
for the three LRP-specific siRNAs used are indicated. siRNA-LRP 9, siRNA-LRP 4 and siRNA-LRP 7 target
bases 207–225, 330–348 and 660–678, respectively.
Pflanz, H., Vana, K., Mitteregger, G., Pace, C., Messow, D., Sedlaczek, C., Nikles, D., Kretzschmar, H. A. 
and Weiss, S. F. T. (2009). Microinjection of lentiviral vectors expressing small interfering RNAs directed against laminin receptor
precursor mRNA prolongs the pre-clinical phase in scrapie-infected mice. J Gen Virol 90, 269–274.
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1.4 Ligation reaction 
 
1.4.1 Map of pTZ57R/T cloning vector 
 
 
 
 
1.5 Preparation of competent bacteria 
 
1.5.1 T-solution 
250µl T-solution (A) (Fermentas) 
250µl  T-solution (B) (Fermentas) 
Combine  
Store on ice 
 
1.5.2 LB medium 
1%  Sodium chloride  
0.5%  Yeast extract  
1%  Tryptone  
Make up to final volume with dH2O  
Sterilise for 20 min at 151 lbq  
Store at 4°C 
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1.6 Transformation 
 
1.6.1 0.1M IPTG stock solution 
1.2g IPTG 
Add dH2O to a final volume of 50ml 
Filter sterilize through a 0.2µm filter unit 
Store at 4°C 
 
1.6.2 50mg/ml X-Gal stock solution 
50mg X-Gal 
Add dimethylformamide to a final volume of 1ml 
Filter sterilize through a 0.2µm filter unit 
Store at -20°C 
 
1.6.3 LB plates containing 50µg/ml ampicillin 
1.5% Bacto-agar 
In LB medium (Appendix 1.4.2) 
Sterilise for 20min at 151 lbq 
Cool to 55°C 
Add ampicillin to a final concentration of 50µg/ml 
Pour approximately 25ml of solution into separate 100mm Petri-dishes 
Allow liquid agar to solidify 
Seal Petri-dishes with parafilm 
Store at 4°C  
 
 
1.6.4 LB plates containing 50µg/ml ampicillin, 05mM IPTG and 40µg/ml X-Gal 
LB plates containing 50µg/ml ampicillin (Appendix 1.4.4) 
100µl 0.1M IPTG stock solution (Appendix 1.4.1) 
20µl 50mg/ml X-Gal stock solution (Appendix 1.4.2) 
Spread the IPTG and X-Gal onto the LB-ampicillin plates 
Allow the components to absorb for 30min at 37°C prior to plating of cells 
 
1.6.5 2M Mg2+ stock 
20.33g MgCl2.6H2O 
24.65g MgSO4.7H2O 
Add distilled water to a final volume of 100ml 
Filter sterilize 
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1.6.6 SOC medium 
2g Tryptone 
0.5g Yeast extract 
1ml 1M NaCl 
0.25ml 1M KCl 
1ml 2M Mg2+ stock, filter sterilized (Appendix 1.5.5) 
1ml 2M glucose, filter sterilized 
Add tryptone, yeast extract, NaCl and KCl to 97ml distilled water. 
Sterilise for 20min at 151 lbq 
Cool to room temperature 
Add 2M Mg2+ and 2M glucose, each to a final concentration of 20mM 
Add distilled water to a final volume of 100ml 
Store at 4°C 
 
1.6.7 LB plates containing 50µg/ml kanomycin 
1.5% Bacto-agar 
In LB medium (Appendix 1.4.2) 
Sterilise for 20min at 151 lbq 
Cool to 55°C 
Add kanomycin to a final concentration of 50µg/ml 
Pour approximately 25ml of solution into separate 100mm Petri-dishes 
Allow liquid agar to solidify 
Seal Petri-dishes with parafilm 
Store at 4°C  
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1.7 Immunofluorescence 
 
1.7.1 Paraformaldehyde (4%)$
 
Solution A  
0.14M  Sodium dihydrogen orthophosphate (anhydrous)  
Make up to final volume with distilled water 
 
Solution B  
0.63M  Sodium hydroxide  
Make up to final volume with distilled water  
 
Dissolve:  
4 %  Paraformaldehyde in  
83%  Solution A  
17%  Solution B  
 
Make up to final volume with distilled water 
Heat to approximately 80°C until solution clears  
Filter and store at 4°C 
 
1.7.2 Phosphate Buffered Saline (PBS): 1X 
136.9mM  Sodium chloride  
2.68mM  Potassium chloride  
10.1mM  Disodium hydrogen phosphate dodecahydrate  
1.76mM  Potassium dihydrogen phosphate  
Adjust pH to 7.3  
Make up to final volume with distilled water  
Sterilise for 20 min at 151 lbq  
Store at 4°C 
 
1.7.3 0.5% Bovine serum albumin (BSA) 
0.5% BSA  
In PBS (Appendix 1.6.2) 
Store at 4°C 
 
1.7.4 0.25% Triton X-100 + 0.5%BSA 
0.25% Triton X-100 
In 0.5% BSA (Appendix 1.6.3) 
Store at 4°C 
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1.8 Cell lysis 
 
1.8.1 Lysis buffer 
10mM  Tris-HCl (pH7.5) 
100mM NaCl 
10mM  Ethylenediaminetetraacetic acid (EDTA) 
0.5%   Nonidet-P40 
0.05%  Deoxycholate 
Make up to final volume with distilled water 
Store at 4°C 
 
1.9 Protein Quantification 
 
1.9.1 BCA reagent (Sigma-Aldrich) 
Reagent A: Bicinchoninic acid solution 
Reagent B: Copper (II) sulphate solution 
Mix Reagent A and B in a 1:50 ratio immediately before use 
 
1.10 Electrophoresis: SDS-PAGE 
 
1.10.1 5x Laemmli sample buffer 
60mM  Tris-HCl (pH 6.8) 
2%  SDS  
10%  Glycerol 
5%  β-mercaptoethanol  
0.01%  Bromophenol blue 
Make up to final volume with distilled water 
Aliquot and store at -20°C 
 
1.10.2 12% SDS-PAGE gel 
1.10.2.1 Separating gel  
12%   Acrylamide  
0.1%   NN‟-methylenebisacrylamide  
375mM  Tris-HCl (pH 8.8) 
0.2%   SDS  
Make up to final volume with distilled water 
 
Just before use add:  
1mM   Ammonium persulphate  
0.25%   N,N,N‟N‟-tetramethylenediamine (TEMED)  
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1.10.2.2 Stacking gel 
12%   Acrylamide  
0.1%   NN‟-methylenebisacrylamide  
125mM  Tris-HCl (pH 6.8)  
0.2%   SDS  
Make up to final volume with distilled water 
 
Just before use add:  
1mM   Ammonium persulphate  
0.25 %   TEMED 
 
 
1.10.3 Electrophoresis buffer 
25mM  Tris (pH8.3) 
192mM  Glycine  
0.1%   SDS 
Make up to final volume with distilled water 
 
1.11 Western Blotting 
 
1.11.1 Transfer buffer 
25mM  Tris-HCl (pH 8.3) 
192mM Glycine 
20%  Methanol 
Make up to final volume with distilled water 
Store at -4°C 
 
 
1.11.2 PBS-Tween 
0.1% Tween 20 
In PBS (Appendix 1.6.2) 
Store at 4°C 
 
1.11.3 Blocking buffer 
3% Bovine serum albumin (BSA) 
In PBS-Tween (Appendix 1.10.2) 
 
1.11.4 SuperSignal West Pico Chemiluminscent Substrate kit (Pearce): working 
solution 
Before use mix: 
50% Luminol/Enhancer solution 
50% Stable peroxidase buffer 
Store in the dark 
 
 
